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Foreword 
 
Personalized medicine, a discipline enabled by genetic, biopharma, diagnostic, and information and 
communications (ICT) technologies attempts to tailor disease treatment to individual patients. 
Personalized medicine is rapidly emerging as a state-of-the-art approach to diagnostics and therapeutics 
and is beginning to revolutionize our health care system, promising better medicine for all. 
COST – European Cooperation in Science and Technology – opened up the field of personalized 
medicine in 1986 when, as part of the Biomedicine and Molecular Biosciences Domain, it sanctioned a 
research network (aka COST Action) to recruit trial subjects based on differences in metabolic capacity 
(COST Action B1, 1986). Since then, progress in technology, along with a growing understanding of 
individual susceptibility to disease and treatment effects, has led to new concepts in translational science 
such as the Virtual Patient Model. These developments are transforming the way we think about health 
and disease. 
Interdisciplinary methods are facilitating the creation of integrated data sets that incorporate biological, 
chemical, and clinical observations through the use of sophisticated software and hardware. Mathematics, 
physics, and chemistry are all employed in all aspects of ICT, including gathering data, simulating 
biological processes, and visualizing the system as a whole. 
Despite the advances, considerable challenges remain in realizing the full potential of personalized 
medicine, including creating a greater awareness among global stakeholders. Initiatives in Europe, 
including the UK’s Stratified Medicine Innovation Platform, Sweden’s Biobank Program, BIOMEDREG in 
the Czech Republic, and the Munich Biotech Cluster in Germany, are working toward this goal, but the 
efforts are still modest. Our conference aims to highlight the current activities, along with future 
possibilities, to a broader audience. Overcoming identified obstacles to making personalized medicine 
more available for patients requires a focus on basic, translational, and regulatory science, especially in 
the areas of ethical, legal, and social issues. Improvement in patient care must remain a priority 
throughout the collection and use of information on an individual patient’s genome and its downstream 
products including transcriptomes, proteomes, and metabolomes. This will require a significant 
exploration of strategic relationships between all interested parties with proposals for further 
interdisciplinary collaborations involving mathematics, physics, chemistry, and ICT. 
Connecting high-quality trans-disciplinary scientists through programs such as COST can support 
capacity building and increase the impact of personalized medicine research on regulatory bodies, 
decision makers, pharmaceutical companies, and payers. Such collaborations could enable breakthrough 
scientific developments, lead to new concepts and products, and contribute to Europe’s strength in 
research and innovation, while reforming the health care system. With this vision in mind, the Chairs of 
the COST Domains of ICT, Biomedicine and Chemistry used their privileged positions to gather their 
corresponding scientific communities together with science policy makers (António Correia de Campos 
MEP – European Parliament, Irene Norstedt – European Commission, Stavros Malas – Minister of Health 
of Cyprus) and patients’ associations (Mary Baker – former President of European Parkinson Disease 
Association) for the upcoming conference. We believe the three domains have succeeded in putting 
together the necessary stakeholders to prepare the ground for significant advancement in science and 
technology, and for critical influence on science policy. The success in attracting such a significant and 
diverse cadre of policy makers, patients, and top scientists is the full justification for another conference 
on personalized medicine. The conference will take place from June 17 to 22, 2012 at Golden Bay Beach 
Hotel in Larnaca, Cyprus (http://www.cost.eu/events/pemed). This event will be not only published in 
proceedings but will also be featured on YouTube. 
Soulla Louca 
COST DC Information and Communications Technologies 
Roland Pochet 
COST DC Biomedicine and Molecular Biosciences 
Dieter Schinzer 
COST DC Chemistry and Molecular Sciences and Technology 
3 
 
 
Programme  
 
Day 0 | Sunday 17 June 2012 
 
14:00 – 18:00 Arrival at Larnaca airport 
16:30 – 19:30 Registration at the COST desk 
19:30 – 22:00 Welcome cocktail and dinner 
 
Day 1 | Monday 18 June 2012 
08:30 – 09:00 Registration at the COST desk (latecomers) 
  
09:00 – 09:50 Conference Opening 
09:00 – 09:05 Soulla Louca (5’) Conference Chair / Chair of the COST Domain Committee for 
Information and Communication Technologies (ICT) / 
Associate Professor, University of Nicosia, CY 
09:05 – 09:10 Vassilios Tsakalos (5’) Director General, Research Promotion Foundation, CY 
09:10 – 09:25 Stavros Malas (15’) Minister of Health, CY 
09:25 – 09:40 António Correia 
de Campos (15’) 
MEP and Science and Technology Options Assessment 
(STOA) Panel chair, European Parliament 
09:40 – 09:50 Primož Pristovšek (10’) Vice-President, COST Committee of Senior Officials 
09:50 – 10:20 Coffee break 
  
10:20 – 12:40 Session 1: Research Challenges and Future Strategies 
 
Chair: António Correia 
de Campos 
MEP and Science and Technology Options Assessment 
(STOA) Panel chair, European Parliament 
10:20 - 10:40 Morag Park (20’) Scientific Director,  Institute of Cancer Research, Canadian 
Institutes of Health Research, CA 
Personalised Medicine Research and Canada 
10:40 – 11:20 Irene Norstedt (30’+10’) Deputy Head of Unit, Unit F.5: Personalised medicine, 
Directorate F – Health, DG Research and Innovation, 
European Commission 
Personalised Medicine Research at European level 
11:20 – 12:00 Mary Baker (30’+10’) President, European Brain Council, UK 
Perception of what personalised medicine is as seen by 
patient organisations 
12:00 – 12:40 
 
Jacques Haiech  
(30’+10’) 
Professor, University of Strasbourg, FR 
Education and Personalised Medicine: The challenge 
12:40 – 14:00 Lunch 
  
14:00 – 16:00 Session 2: Empowering the Patients 
 
Chair: Roland Pochet Conference Vice-Chair / Chair of the COST Domain 
Committee for Biomedicine and Molecular Biosciences 
(BMBS) / Professor, Université libre de Bruxelles, BE 
14:00 – 14:40 Michael Strupp 
(30’+10’) 
Professor, Ludwig-Maximilians-University Munich, DE 
How to improve the diagnosis and treatment of patients with 
vertigo and dizziness: The German Vertigo Center 
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14:40 – 15:20 Jonathan Knowles 
(30’+10’) 
Professor, Ecole Polytechnique Fédérale de Lausanne 
(EPFL), CH / Institute for Molecular Medicine Finland (FIMM), 
FI 
The Molecular Personalization of Medicine: Future vision or 
immediate necessity? 
15:20 – 16:00 Adriano Henney 
(30’+10’) 
Program Director, German Virtual Liver Network 
Lecture title TBA 
16:00 – 16:30 Coffee break 
  
16:30 – 17:45 Roundtable Discussion with Stakeholders 
 
Chair: Constantinos N 
Phellas 
Vice Rector for Faculty & Research, President of the Cyprus 
Sociological Association, CY 
 
Aleksandar Dimovski Dean, University St Cyril and Methodius, F.Y. Republic of 
Macedonia 
 
Jacques Haiech Professor, University of Strasbourg, FR 
 
Jonathan Knowles Professor, Ecole Polytechnique Fédérale de Lausanne 
(EPFL), CH / Institute for Molecular Medicine Finland (FIMM), 
FI 
 
K.C. Nicolaou Chairman of the Department of Chemistry, The Scripps 
Research Institute, US 
 
Irene Norstedt Deputy Head of Unit, Unit F.5: Personalised medicine, 
Directorate F – Health, DG Research and Innovation, 
European Commission 
 
Michael Strupp Professor, Ludwig-Maximilians-University Munich, DE 
 
Albrecht von Müller Director, Parmenides Foundation, DE 
  
17:45 – 19:45 Poster Session 
 
Co-Chair: Roland 
Pochet 
Professor, Université libre de Bruxelles, BE 
 
Co-Chair: Mira Marcus-
Kalish 
Director for International Research, Tel Aviv University, IL 
20:00 – 22:00 Dinner and poster prize award 
 
Day 2 | Tuesday 19 June 2012 
 
 
09:00 – 12:50 Session 3: ICT in action in Personalised Medicine 
 
Chair: Soulla Louca Associate Professor, University of Nicosia, CY 
09:00 – 09:40 Richard Frackowiak 
(30’+10’) 
Head of the Department of Clinical Neurosciences, Le Centre 
hospitalier universitaire vaudois (CHUV), CH 
Lecture title TBA 
09:40 – 10:20 Hans Lehrach (30’+10’) Director, Max Planck Institute for Molecular Genetics, DE 
The future of medicine 
10:20 – 11:00 María Berdasco 
(30’+10’) 
Associate Researcher, Bellvitge Biomedical Research 
Institute (IDIBELL), ES 
Cancer Epigenetics 
11:00 – 11:30 Coffee break 
11:30 – 12:00 Christos A. Nicolaou 
(20’+10’) 
Principal Research Scientist, Global Scientific Informatics, Eli 
Lilly and Company, US 
Evolving Approaches to Drug Selectivity and Designed 
Polypharmacology 
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12:00 – 12:30 Cristiana Pavlidou 
(20’+10’) 
GOLDEN HELIX Institute of Biomedical Research, GR 
Development of centralized National Genetics databases and 
their implications for personalized medicine 
12:30 – 12:50 Christos Kannas 
(15’+5’) 
Special Scientist, University of Cyprus, CY 
Towards a modular Web-based Workflow environment for 
enabling large scale Virtual Screening in Cancer 
Chemoprevention Research 
13:00 – 14:30 Lunch 
  
14:30 – 18:20 Session 4: Natural Products as a Source for New Drugs 
 
Chair: Dieter Schinzer Conference Vice-Chair / Chair of the COST Domain 
Committee for Chemistry and Molecular Sciences and 
Technologies / Professor, Otto-von-Guericke University 
Magdeburg, DE 
14:30 – 15:30 Maurizio Botta (45’+15’) Professor, University of Siena, IT 
Three different approaches to target the T315I mutation: 
ATP-competitive, ATP-non-competitive and 14-3-3 inhibitors 
15:30 – 16:30 Jef De Brabander 
(45’+15’) 
Professor, UT Southwestern Medical Center, US 
Natural Products: An Opportunity for Discovery 
16:30 – 17:00 Coffee break 
17:00 – 17:20 Andrea Danani (15’+5’) Professor, University of Applied Sciences of Southern 
Switzerland, CH 
System Information Therapy and Personalized Medicine 
17:20 – 17:40 Yannis Missirlis 
(15’+5’) 
Professor, University of Patras, GR 
All the appropriate signals are necessary for engineering 
proper tissues 
17:40 – 18:00 
 
Andreani Odysseos 
(15’+5’) 
Director of Biomedical Research, EPOS-Iasis, R&D, CY 
γ-Tocotrienol, a nutrient-derived natural product, induces 
differential modulation of the therapeutic efficacy of anti-
EGFR Tyrosine Kinase Inhibitors 
18:00 – 18:20 
 
Harald Schmidt (15’+5´) Professor, Maastricht University, NL 
Personalised cardiovascular medicine: From antioxidants to 
validated molecular sources and targets of oxidative stress 
19:00 – 21:00 Dinner 
21:00 -  Evening lecture: K.C. 
Nicolaou 
Chairman of the Department of Chemistry, The Scripps 
Research Institute, US 
Molecules that Changed the World 
 
Day 3 | Wednesday 20 June 2012 
 
09:00 – 15:30 Session 5: Constellation Thinking in the Diagnosis and Therapy 
 
Chair: Srecko Gajovic Editor-in-Chief Croatian Medical Journal / University of 
Zagreb, HR 
09:00 – 09:40 Stephane Berghmans 
(30’+10’) 
Head of Unit , European Medical Research Councils 
(EMRC), European Science Foundation, FR 
Personalised Medicine for the European citizen - an ESF 
Forward Look 
09:40 – 10:20 Anne Bruinvels 
(30’+10’) 
CEO, Elixior Ltd, UK 
Personalised Medicine: The Future is Now 
10:20 – 11:00 Ursula Gundert-Remy 
(30’+10’) 
Federal Institute for Risk Assessment, DE 
The choice of the right drug and the choice of the right dose 
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11:00 – 11:30 Coffee break 
11:30 – 12:10 Barbara Prainsack 
(30’+10’) 
Professor, Brunel University London, UK 
Personalised Medicine and the Citizen: A Participatory Turn 
in Health? 
12:10 – 13:10 Albrecht von Müller 
(45+15’) 
Director, Parmenides Foundation, DE 
Constellatory diagnostics 
13:10 – 14:30 Lunch 
  
14:30 – 14:50 Maria Laura Bolognesi 
(15’+5’) 
Associate Professor, University of Bologna, IT 
Styrylquinolines as amyloid chemical probes and 
theranostics in Alzheimer’s and prion diseases 
14:50 – 15:10 Darko Bosnakovski 
(15’+5’) 
Assistant Professor, University "Goce Delcev" Stip, former 
Yugoslav Republic of Macedonia 
Gene corrected FSHD-IPS cells, once step closer to cell 
therapy for Facioscapulohumeral muscular dystrophy 
15:10 – 15:30 Marija Krstic-
Demonacos (15’+5’) 
Lecturer, University of Manchester, UK 
Dynamic Modelling for Personalised Cancer Care   
16:00 – 19:00 Excursion / Beach volleyball 
19:30 – 22:00 Dinner at Ouzeri Tavern 
 
Day 4 | Thursday 21 June 2012 
  
09:00 – 13:10 Session 6: Personalised health 
 
Chair: Dina Simunic University of Zagreb, HR 
09:00 – 09:40 Davor Milicic (30’+10’) University of Zagreb, HR 
Lecture title TBA 
09:40 – 10:20 Kamran Sayrafian 
(30’+10’) 
National Institute of Standards and Technology (NIST), US 
Personalised Health: An ICT Perspective 
10:20 – 11:00 Dina Simunic (30’+10’) University of Zagreb, HR 
Wireless in-body positioning methods for personalized 
medicine 
11:00 – 11:30 Coffee break 
11:30 – 12:00 Paul Mitcheson 
(20’+10’) 
Senior Lecturer, Imperial College London, UK 
Energy harvesting in health care applications 
12:00 – 12:30 Emmanuel Mikros 
(20’+10’) 
University of Athens, GR 
Metabonomics: A new tool in diagnosis and personalised 
medicine 
12:30 – 12:50 Saulius Klimasauskas 
(15’+5’) 
Head of Department, Insitute of Biotechnology, Vilnius 
University, LT 
Chemo-enzymatic approaches to genome-wide profiling of 
cytosine modifications   
12:50 – 13:10 Alain van Gool (15’+5’) Coordinator for Personalised Medicine, Netherlands 
Organization for Applied Scientific Research (TNO), NL 
Towards Personalised Medicine in Metabolic Disease 
13:10 – 14:30 Lunch 
  
14:30 – 18:00 Session 7: New Targets and Inhibitors Based on Epigenetics 
 
Chair: Dieter Schinzer Professor, Otto-von-Guericke University Magdeburg, DE 
14:30 – 15:30 Wim Vanden Berghe Professor, University of Antwerp 
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(45’+15’) Epigenomic profiling of phytochemical effects in cancer-
inflammation and cardiovascular disease: challenges & 
pitfalls 
15:30 – 16:30 Arasu Ganesan 
(45’+15’) 
Professor, University of East Anglia, UK 
Natural Products and Epigenetic Drugs 
16:30 – 17:00 Coffee break 
17:00 – 18:00 Manfred Jung (45’+15’) Professor, University of Freiburg, DE 
Epigenetics and available epigenetic drugs: An overview 
18:00 – 18:30 Closing session: Conference wrap-up 
 
Chair : Mira Marcus-
Kalish 
Director for International Research, Tel Aviv University, IL 
 
Soulla Louca Conference Chair / Chair of the COST Domain Committee for 
Information and Communication Technologies (ICT) / 
Associate Professor, University of Nicosia, CY 
 
Roland Pochet Conference Vice-Chair / Chair of the COST Domain 
Committee for Biomedicine and Molecular Biosciences 
(BMBS) / Professor, Université libre de Bruxelles, BE 
 
Dieter Schinzer Conference Vice-Chair / Chair of the COST Domain 
Committee for Chemistry and Molecular Sciences and 
Technologies / Professor, Otto-von-Guericke University 
Magdeburg, DE 
20:00 – 23:00 Conference dinner 
 
Day 5 | Friday 22 June 2012 
 
08:00 – 10:00 Breakfast and departure 
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Invited Speakers, Roundtable 
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Organising Committee Members 
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Dr Mary Baker 
Position President 
Organisation European Brain Council 
Town Woking 
Country United Kingdom 
E-mail bobandmary@btinternet.com 
Biography Mary Baker, MBE, is President of the European Brain Council, immediate past President 
of the European Federation of Neurological Associations, Consultant to the World Health 
Organisation (WHO) and Chair of the Working Group on Parkinson’s Disease formed by 
the WHO in May 1997.   
In 2008 the Council of Europe re-appointed Mary for a second term until March 2012 as 
one of the patient representatives to serve on the Management Board of the European 
Medicines Agency (EMA), and in the same year she was appointed to the IMI JU Scientific 
Committee.  In 2007 Mary was appointed to the Council of the Association of the British 
Pharmaceutical Industry (ABPI) and also a Member of the ABPI Code of Practice.  Other 
significant appointments include Director at Large for the World Stroke Association, former 
patient editor of the British Medical Journal (BMJ). 
In June 2011 Mary joined the Ethical Issues sub committee of the Faculty of 
Pharmaceutical Medicines for a period of three years and in July 2011 was invited to 
become a member of the Network of Global Agenda Councils for a term of one year.  In 
2009 Mary received the prestigious British Neuroscience Association Award for 
Outstanding Contribution to British Neuroscience and for Public Service.   
Mary is a Patron of the European Parkinson’s Disease Association (EPDA) and the former 
past President of EPDA, a position to which she was elected in 1992 when the EPDA was 
first formed. Mary retired as Chief Executive of the Parkinson’s Disease Society of the 
United Kingdom in 2001 where she had worked for 18 years.  
Abstract Perception of what personalised medicine is as seen by patient organisations 
Personalised Medicines – Society’s Perspective 
Today clinicians diagnose and treat based on symptoms and a subjective interpretation of 
symptoms.  In the future, the clinicians will diagnose and treat based on biology and select 
medication based on an objective evaluation of the benefit/risk for the individual patient.  
This is an exciting step forward but will be very dependent upon the ability to communicate 
to general society the understanding of benefit/risk.  We should build the doctor/patient 
relationship in order that decisions can be taken jointly by the patient and the clinician, 
thereby increasing the responsibility of society in its management of health. 
 
 
Dr María Berdasco 
Position Senior Researcher 
Organisation Bellvitge Biomedical Research Institute (IDIBELL) 
Department Cancer Epigenetics and Biology Program (PEBC) 
Town L'Hospitalet de Llobregat- Barcelona 
Country Spain 
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E-mail mberdasco@idibell.cat 
Biography Dr María Berdasco (Luarca, Asturias, Spain, 1978) is a senior researcher in the Cancer 
Epigenetics and Biology Program (PEBC) at IDIBELL (Barcelona, Spain) and has been 
trained on epigenetics during the last decade. She graduated in Molecular Biology with 
Honors from the Universidad de Oviedo in 2001, where she also obtained her Ph.D 
degree specializing in plant epigenetics in 2005. Her stay at the Spanish National Cancer 
Research Center (CNIO, Madrid) during four years (2004-2008) and the actually position 
at PEBC-IDIBELL allows her to work with the state-of-the-art technology in the field of 
Epigenetics. Furthermore, she is involved in the coordination of international research 
consortia of several European projects, covering funding schemes from the Cooperation 
Scheme in FP6 and FP7 to COST actions as well as various other privately funded 
endeavors and Spanish Programs (FIS). She is also a member of the Ethical Committee 
of the IDIBELL. Her current research is devoted to the establishment of the epigenome 
maps of normal and transformed cells, the study of the interactions between epigenetic 
modifications and non-coding RNAs, and the development of new epigenetic drugs for 
cancer therapy. 
Abstract Cancer Epigenetics 
Initially, cancer was thought to be solely a consequence of genetic changes in key tumor-
suppressor genes and oncogenes that regulate cell proliferation, DNA repair, cell 
differentiation, and other homeostatic functions. However, recent research suggests that 
these alterations could also be due to epigenetic disruption. The study of epigenetic 
mechanisms in cancer, such as DNA methylation, histone modification, nucleosome 
positioning and micro-RNA expression, has provided extensive information about the 
mechanisms that contribute to the neoplastic phenotype through the regulation of 
expression of genes critical to transformation pathways. Regarding DNA methylation, the 
low level of CpG methylation in tumors compared with that in their normal-tissue 
counterparts and the hypermethylation of the CpG islands in the promoter regions of tumor-
suppressor are accepted as being a common feature of human cancer. Due to the 
complexity of permutations and combinations, less is known about the patterns of histone 
modification disruption in human tumors. Results have shown that the CpG promoter 
hypermethylation event in tumor-suppressor genes in cancer cells is associated with a 
particular combination of histone markers and the opposite of that observed in normal cells. 
Aberrations in the epigenetic profiles, with respect to DNA methylation and histone 
modifications, could also be a consequence of genetic disruption of the epigenetic 
machinery, such as disruption of the histone methyltransferase NSD1 in neuroblastomas or 
mutations in the histone deacetylase HDAC2 in colon cancer. The deregulation of miRNA 
expression has also been linked to tumor progression. Changes in miRNA expression in 
cancer can be achieved through various mechanisms, including impairment of miRNA 
processing machinery, such as the recently identified mutations of TRBP2 (an essential 
functional partner of the DICER1 complex) in sporadic and hereditary carcinomas with 
microsatellite instability or by CpG hypermethylation of miRNas with tumor-suppressor 
properties.  The possibility of “resetting” the abnormal cancer epigenome by applying 
pharmacologic or genetic strategies will be also discussed. 
 
 
Dr Stephane Berghmans 
Position Head of Unit 
Organisation European Science Foundation 
Department European Medical Research Councils 
Town Strasbourg 
Country France 
E-mail sberghmans@esf.org 
Biography Stephane Berghmans is a Doctor in Veterinary Medicine who obtained his Ph.D. studying 
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epigenetic mechanisms of inheritance and developing expertise in genetics and molecular 
biology at the University of Liege (Belgium).  He then became a postdoctoral fellow at 
Harvard Medical School in Prof. Thomas Look's laboratory, Dana Farber Cancer Institute, 
where he established zebrafish as a model organism to study cancer.  Seeing the 
opportunity for a more direct application of zebrafish in drug discovery, he moved to the 
biotech sector and joined DanioLabs (Cambridge, UK) in 2004 where he headed 
development, implementation and automation of zebrafish drug discovery and liability 
assays for early in vivo compound screening. He moved to Portland (Oregon, USA) in 2008 
where he joined Znomics as Director of Biology, installing new research teams and 
facilities. Rich from a strategic experience in the private sector and interested in science 
policy, he joined the European Science Foundation in June 2009 as Head of the Biomedical 
Sciences Unit. In this position he manages the secretariat general for the European Medical 
Research Councils (EMRC) with activities spanning from science management to scientific 
networks and a very strong emphasis on science policy and strategy. 
Abstract Personalised Medicine for the European citizen - an ESF Forward Look 
In recognizing the importance of Personalised Medicine the European Medical Research 
Councils (EMRC) commissioned a Forward Look to gain insight into the needs for research 
programmes and infrastructures, policy and education. Forward Looks are foresight 
exercises that enable Europe’s scientific community, in interaction with policy makers, to 
develop medium- to long-term views and analyses of future research developments with 
the aim of defining research agendas at national and European level. The challenges 
ahead are significant, and it is becoming clear that biological systems operate in a far more 
complex way that we might have previously thought. Nevertheless this approach is starting 
to yield results and it is predicted that these technologies will generate innovative therapies, 
limit adverse effects of treatments, increase the quality of clinical care, create an optimal fit 
between a patient and a treatment, and decrease the costs of healthcare. But Personalised 
Medicine will have a broader impact on society as increased transparency of individual 
biological inequalities will affect basic issues such as risk, responsibility, and solidarity, 
raising complex social and ethical questions. For these reasons the Forward Look is a 
collaborative effort between all Standing Committees under the auspices of the European 
Science Foundation (ESF): Life, Earth & Environmental Sciences (LESC); Humanities 
(SCH); Social Sciences (SCSS); and Physics & Engineering (PESC). The overall aim of 
this Forward Look is to analyse in a systematic way the complex and constantly moving 
field of personalised medicine to provide timely policy advice that will help prepare Europe 
for the likely changes in how society deals with health and disease. The final stakeholder 
conference will have taken place in April 2012 to finalise and prioritise recommendations to 
be published in a final report with a launch in summer 2012. 
 
Prof. Maurizio Botta 
Position Professor 
Organisation University of Siena 
Department Dipartimento Farmaco Chimico Tecnologico 
Town Siena  
Country Italy 
E-mail botta.maurizio@gmail.com 
Biography Prof. Maurizio Botta, PhD (U.N.B. – Canada) is full Professor of Medicinal Chemistry at the 
Faculty of Pharmacy, University of Siena, from November 1st 2009 is Dean of the same 
Faculty of Pharmacy and, from January 1st 2008, Adjunct Professor in Temple University’s 
College of Science and Technology, in the Department of Biology, Philadelphia (USA). 
From November 2002 to October 2008 has been Head of the Dipartimento Farmaco 
Chimico Tecnologico of the University of Siena. 
EU expert for reviewing projects belonging to the TMR research program, for the Mid-Term 
review of the approved TMR projects. He is Executive Guest Editor of “Current 
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Pharmaceutical Design” in the field of Anti-Angiogenesis Agents, EU expert in the panel 
“Quality of Life” for reviewing projects belonging to the “Life sciences, genomics and 
biotechnology for health” research program. Projects reviewer for Italian and Slovenian 
Research Projects, for the Austrian Research Fund (Wissenschaftsfonds-FWF), for the 
Cancer Research UK Programme and actually for “Fondazione Roma”, for the French 
National Research Agency and for Italian Ministery for the Economic Development. He is 
Member of the Editorial Board for “ChemMedChem” (Wiley), from January 2008 Member of 
the Editorial Advisory Board for “Journal of Medicinal Chemistry” and from January 2010 
Member of the Editorial Advisory Board for “Medicinal Chemistry Letters” (ACS). 
He is member of the “Società Chimica Italiana” from 1976, member of the American 
Chemical Society from 1984 and of the QSAR Society from 1997 and, from 1998 to 2004, 
he was member of the “Direttivo della Divisione di Chimica Farmaceutica della Società 
Chimica Italiana”. He was Chairman of 18 scientific schools and meetings, among which 
Schools of Synthetic Methodologies in Medicinal Chemistry of SCI and European 
Workshops in Drug Design and in Drug Synthesis, of European COST Meetings, of the 
“Twelfth FeCheM – conference on Heterocycles in Bio-Organic Chemistry”, “ACS EFMC 
Frontiers in CNS & Oncology Medicinal Chemistry”, “1st iDDi Workshopon Neglected and 
Orphan Diseases” held at University of Siena; he was co-Chairman at the Conference “3rd 
IUPAC-2002 International Symposium on the Chemistry of Natural Products”, Firenze. 
Since 1998, he has contributed to the organization of more than 80 scientific seminars at 
the Dipartimento Farmaco Chimico Tecnologico of Siena University. 
He carries out reviewing activity for well know journals in organic and medicinal chemistry, 
received five Merck Research Laboratories Awards "Academic Development Program in 
Chemistry" (1996, 1997, 1998, 2001, and 2002). 
Since 1988, Prof. Botta is the owner of research funds granted by University, MIUR, CNR, 
EU, and Pharmaceutical Companies. Professor Botta is the author of more than 350 
papers, 9 publications on volumes, 14 patents and more than 150 proceedings at 
congresses. 
His main research areas include chemical studies on beta-lactam antibiotics; total synthesis 
and structure determination of biologically active natural products; synthesis of pyrimidine 
derivatives as antiviral and antitumor agents. 
The following methodologies have been used in such studies: classical methodologies for 
organic synthesis, methodologies for the solid phase synthesis of small molecules, use of 
enzymes, microwave and parallel synthesis; structural studies of biological macromolecules 
(enzymes, receptors, growth factors), studies about structure-function relationship of 
lypases, molecular modeling application on medicinal subjects; Virtual Library Design. 
Abstract Three different approaches to target the T315I mutation: ATP-competitive, ATP-non-
competitive and 14-3-3 inhibitors 
A serious problem in the treatment of Chronic Myeloid Leukemia (CML) is represented by 
the development of resistance to Imatinib (IM, Gleevec®), which is currently used in 
frontline therapy. The insurgence of drug-resistance, especially in the advanced phases of 
the disease, can be caused by both Bcr-Abl-dependent mechanisms (e.g. mutation in the 
kinase domain of the enzyme, Bcr-Abl gene amplification) and Bcr-Abl-independent 
mechanisms (e.g. Src family kinase activation). As a consequence, there is a growing 
interest in developing novel TK inhibitors able to target IM-resistant forms of CML, 
especially the T315I mutant. The application of molecular modeling and combinatorial 
techniques led our Research Group to the identification of three different families of 
compounds active on three different targets: 1) The ATP binding site of the Bcr-Abl T315I 
mutant1; 2) the myristate binding pocket of Bcr-Abl² and 3) the 14-3-3 σ protein.³ While 
coumpounds active on the first two targets represent valuable inhibitor of IM-resistant Bcr-
Abl-dependent forms of leukemia, 14-3-3 σ inhibitors could allow to overcome Bcr-Abl-
dependent and -independent form of resistance targeting an alternative pathway involved in 
the regulation of the causative events of CML. The successful application of these three 
approaches for the inhibition of the T315I Bcr-Abl mutant will be discussed. 
Santucci, M. A.; Corradi, V.; Mancini, M.; Manetti, F.; Radi, M.; Schenone, S.; Botta, M. “C-6 Unsubstituted 
Pyrazolo[3,4-d]Pyrimidines are Dual Src/Abl Inhibitors Effective Against Imatinib Mesylate-Resistant Chronic 
Myeloid Leukemia, Including that Arising from T315I Mutation.” ChemMedChem 2009, 4, 118-126. 
Radi, M.; Crespan, E.; Falchi, F.; Bernardo, V.; Zanoli, S.; Manetti, F.; Schenone, S.; Maga, G.; Botta, M. “Design 
and synthesis of new thiadiazoles and thiazoles targeting the Bcr-Abl T315I mutant: from docking false-positive to 
ATP non-competitive inhibitors” ChemMedChem 2010, 5, 1226-1231.  b) Crespan, E.; Radi, M.; Zanoli, S.; 
Schenone, S.; Botta, M.; Maga, G. “Dual SRC and ABL inhibitors target wild type ABL and the ABLT315I imatinib-
resistant mutant with different mechanisms” Bioorg. Med. Chem. 2010, 18, 3999-4008. 
Corradi V, Mancini M, Manetti F, Petta S, Santucci MA, Botta M. “Identification of the first non-peptidic small 
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molecule inhibitor of the c-Abl/14-3-3 protein-protein interactions able to drive sensitive and Imatinib-resistant 
leukemia cells to apoptosis.” Bioorg. Med. Chem. Lett. 2010, 20, 6133-6137. 
 
Dr Anne Bruinvels 
Position CEO 
Organisation Elixior Ltd 
Town London 
Country United Kingdom 
E-mail anne.bruinvels@elixior.com 
Biography Anne Bruinvels is heading Elixior, an advisory company focused on the development and 
growth of innovative personalized medicine businesses. Also, she recently founded Px 
HealthCare, a company aiming to provide online and mobile personalized healthcare 
support to people with (or at risk of) chronic diseases.  
Previously, Anne established Curidium, a personalized medicine company focused on 
identifying companion diagnostics and therapeutics to treat patients with central nervous 
system disorders more effectively. She started Curidium's business activities in 2001 and 
raised several rounds of angel funding before taking the company public on the AIM of the 
London Stock Exchange in 2006. Anne was Curidium's CEO until late 2007, when she took 
on the role of Chief Scientific Officer. In March 2009, Curidium was sold to Avacta Group 
plc., UK-based diagnostic services provider.  
Prior to founding Curidium, Anne was Scientific Director, Business Development at 
Pharmagene (now Asterand), where she contributed to the growth of the organisation from 
private start-up to publicly listed biotechnology company. Previously, she has led research 
groups, as Head of Neurogenetics, SmithKline Beecham Pharmaceuticals (now 
GlaxoSmithkline) and as Head of Neuroanatomy and co-leader of global schizophrenia 
research at Wyeth. Anne was awarded a PhD scholarship at Sandoz Pharma (now 
Novartis) and obtained her PhD (neuroscience) from Utrecht University (the Netherlands). 
She was presented with the London Biotechnology Network "Young Entrepreneur of the 
Year Award" in 2003. 
Abstract Personalized Medicine: The Future is Now 
Ask a physician what is personalized medicine and he or she will most likely answer: 
“That’s the medicine I practice each day.” Physicians will always try to give each patient the 
treatment that is best for them. However, given that personalized medicine takes into 
account genetic and biological patient information to select the most appropriate treatment 
regimen for a patient, only a handful of personalized drug therapies have recently come on 
to the market.  
This talk will outline the hurdles that personalized medicine needs to overcome, including 
scientific, development, regulatory and reimbursement issues, as well as the grand medical 
possibilities that may lay ahead of us. Oncology, being the therapeutic area most advanced 
in applying personalized medicine, will be exemplified. Furthermore, the role of the 
empowered patient in making personalized healthcare a reality will be discussed. 
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 Prof. Jef De Brabander 
Position Professor 
Organisation UT Southwestern Medical Center 
Department Biochemistry 
Town Dallas 
Country United States 
E-mail jef.debrabander@utsouthwestern.edu 
Biography Jef K. De Brabander is a native of Belgium where he pursued his undergraduate and 
graduate studies at the University of Ghent (with Prof. M. Vandewalle, Ph.D. 1993). 
Following postdoctoral studies with the late Wolfgang Oppolzer at the University of Geneva 
(94-95) and Paul Wender at Stanford University as a NATO and Fulbright-Hays fellow (95-
96), he began his independent career as a junior faculty member at the University of 
Geneva. In 1998, he was recruited to the Department of Biochemistry at the University of 
Texas Southwestern Medical Center at Dallas, where he was promoted to Full Professor in 
2007 and appointed Co-Director of the “Chemistry and Cancer Scientific Program” of the 
Simmons Comprehensive Cancer Center. He was an Alfred P. Sloan Foundation Fellow 
(2001-03), received the “Journal Award” from the editorial boards of Synlett and Synthesis 
(2006) and an Academic Development Award from the Chemistry Council of Merck 
Research Laboratories (2004-08), and is serving on the Scientific Advisory Board of Reata 
Pharmaceuticals, a company he co-founded. Jef was a chartered member of the National 
Institutes of Health Study Section (2007-2011), the Chair of the 51st Gordon Research 
Conference on Natural Products (Tilton, New Hampshire, July 2010) and the ESF-COST 
conference on Natural Products Chemistry, Biology and Medicine III (Maratea, Italy, 
September 2010). 
Abstract Natural Products: An Opportunity for Discovery 
Our laboratory focuses on the synthesis of complex molecular architectures. Synthetic 
targets include both designed and naturally occurring substances with novel structural 
features and interesting biological function. To facilitate the execution of efficient and 
practical syntheses, we also develop novel methodology towards functionality found in 
complex natural products. Taking advantage of the multi-disciplinary research environment 
at UT Southwestern, we integrate our synthetic program with molecular pharmacology, 
biochemistry, and cancer biology. Our group also collaborates on various biomedical 
research projects including the discovery of novel small-molecule activators of programmed 
cell death (apoptosis), orexin receptor agonists for the treatment of narcolepsy, and 
antitumor agents that target the tumor micro-environment. 
 
Prof. Richard Frackowiak 
Position Head of Department 
Organisation Centre Hospitalier Universitaire Vaudois 
Department Clinical Neurosciences 
Town Lausanne 
Country Switzerland 
E-mail richard.frackowiak@gmail.com 
Biography Richard Frackowiak is Professor and head of the Department of Clinical Neurosciences at 
the Université de Lausanne (UNIL) and its Centre Hospitalier Universitaire Vaudois 
(CHUV). He is a co-director of the proposed EU Human Brain Project. 
Formerly Foundation Professor of Cognitive Neurology at University College London (UCL), 
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Director of the Department of Cognitive Studies (DEC) at the Ecole Normale Supérieure in 
Paris, Wellcome Trust Principal Clinical Research Fellow and Vice-Provost of UCL and 
Dean-Director of its Institute of Neurology. He founded the Wellcome Department of 
Imaging Neuroscience in 1994.  
Professor Frackowiak has an MA and MD from Cambridge (Peterhouse), a DSc from 
London University, an honorary medical doctorate from Liege University and an honorary 
professorship from UCL. A Fellow of the Academies of Medical Sciences of the UK, France 
and Belgium, he is a member of the Academia Europaea and a foreign associate of the 
Institute of Medicine of the American Academies. He has served as president of the British 
Neuroscience Association and the European Brain and Behaviour Society. 
He is scientific advisor to the Director-General of INSERM. He has held prestigious visiting 
professorships, a chaire d’excellence from the Agence Nationale de Recherche, editorships 
and international society roles worldwide. He has always shown a commitment to Europe 
and had many advisory positions in the context of FP5 through to the present, including 
chairmanship of the European Research Council (ERC) starting grants committee in Life 
Sciences. 
His interest is in human brain structure and function relationships in health and disease. He 
has recently moved to a more translational strategy in research by using novel image 
classification techniques. His scientific output is highly cited with an h-index of 144. He has 
won the Ipsen, Wilhelm Feldberg and Klaus Joachim Zulch prizes. 
Abstract From group to individual studies with imaging – examples from dementia 
We now know that a single gene mutation may present with multiple phenotypes, and vice 
versa, that a range of genetic abnormalities may cause a single phenotype. As a result, our 
traditional approach to determining disease nosology – eliciting symptoms and signs, 
creating clusters of like individuals and then defining a disease on those criteria - though it 
has served medicine and therapeutics well in the last century and a half, is now outdated. 
Under that traditional model, the collection of data is subjective, depending as it does on 
patient-doctor interactions, and that may be why it has not generated fundamental 
breakthroughs in our understanding of the pathophysiology of psychiatric and neurological 
diseases. 
What lies ahead? It is time to radically overhaul our epistemological approach to brain 
disease. We now know a great deal about brain structure and function. From genes, 
through functional protein expression, to cerebral networks and functionally specialised 
areas defined via physiological cell recording and microanatomy, we have accumulated a 
mass of knowledge about the brain that defies easy interpretation. Advances in information 
technologies, from supercomputers to distributed and interactive databases, now make 
integration of very large and diverse datasets and advanced data-led analysis possible. 
The application of modern computerized automated techniques for analyzing structural and 
functional brain images are leading to real advances in the application of advanced 
neuroimaging to clinical practice in ways undreamed of only a short time ago. One major 
advance is the development of image classification techniques that put diagnosis of the 
individual at the centre of the enterprise. Another is the application of data-mining 
techniques to help classify patients according to disease mechanisms rather than simple 
phenomenology. Finally multi-modal and multi-modal imaging approaches are leading to a 
redefinition of the dementias in terms of brain system diseases. These ideas will be 
illustrated with reference to the human dementias. These will serve as exemplars of the 
new nosology, which will be brought about by new mathematics, high performance 
computing and by federation of existing and future clinical and neuroscientific data. 
 
Prof. A. Ganesan 
Position Professor 
Organisation University of East Anglia 
Department Pharmacy 
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Town Norwich 
Country United Kingdom 
E-mail a.ganesan@uea.ac.uk 
Biography Prof. Ganesan obtained a BSc (Hons) in Chemistry at the National University of Singapore 
(1986). He did his PhD in synthetic methodology and total synthesis under the supervision 
of Clayton Heathcock at the University of California-Berkeley (1992) followed by a 
postdoctoral stint with Gregory Verdine at Harvard University. In 1993, he joined the 
Institute of Molecular and Cell Biology in Singapore as a Senior Research Chemist at the 
Centre for Natural Product Research and in 1996 became Principal Investigator of the 
Institute’s Medicinal and Combinatorial Chemistry group. In 1999 he joined the University of 
Southampton as a Reader in the Combinatorial Chemistry Centre for Excellence. In 2011 
he became the Chair of Chemical Biology at UEA’s School of Pharmacy. 
Abstract Natural Products and Epigenetic Drugs 
Historically, natural products have been an important source of drugs either as crude 
extracts or in purified form. Nevertheless, the screening of natural products has been 
downsized in the pharmaceutical industry. The presentation will discuss the unique 
chemical space occupied by natural products compared to synthetic compounds and their 
favourable physicochemical properties. Examples will be provided of natural product 
inhibitors of epigenetic enzymes and SAR studies by total synthesis. 
 
 Prof. Ursula Gundert-Remy 
Position Professor 
Organisation Federal Institute for Risk Assessment 
Town Berlin 
Country Germany 
E-mail ursula.gundert-remy@bfr.bund.de 
Biography Prof. Ursula Gundert-Remy has studied human medicine. After her doctorate she 
underwent postdoctoral training in pharmacology and toxicology as well as in internal 
medicine. At the academic level she progressed by becoming the “habilitation”. After 
finishing training, she became the head of the medical reviewers in the former Federal 
Health Office in Berlin, Germany, for 9 years. Thereafter she returned to academia and 
became full professor and chair holder in Clinical Pharmacology at Goettingen University, 
Germany. The last 12 years before her retirement, Prof. Gundert-Remy was the chair of the 
Department of Safety of Substances and Products at the Federal Institute for Risk 
Assessment. Prof. Gundert-Remy is now Guest Professor at Charité, the Medical Faculty in 
Berlin, Germany and Guest Scientist in the Federal Institute for Risk Assessment.  
Prof. Gundert-Remy was continuously working in the field of pharmaco-/toxicokinetics and -
dynamics using different approaches, among them modelling to enable prediction of effects 
and to elucidate mechanisms. 
Abstract The choice of the right drug and the choice of the right dose 
The diagnosis of a disease has been based on typical signs and symptoms and on typical 
clinical findings. However, many diseases are rather heterogeneous concerning the 
underlying cause and hence, the disease progression and the selection of the appropriate 
treatment should be tailored according to the subtype present in a particular patient. 
Subtypes of a disease have been identified on clinical findings. However, identification of 
the molecular disease mechanisms allows specific subtyping and provides a handle for 
predicting the course of the disease and the appropriate therapeutic choice. Examples are 
given in cardiology by subtype-specific treatment for the three most common LQT 
syndromes, and in oncology by the selection of the treatment regimen in breast cancer and 
in leukaemias. 
Even with the right drug treatment the response intensity may vary individually. Genotype 
specific drug responses have been described as early as 1976 and the first COST Action in 
Biomedicine (COST B1) was devoted to the question how to identify subjects with 
genetically impaired drug metabolism. Several important and often used drugs such as 
antidepressants, clopidogrel, platelet aggregation inhibitors and also Warfarin, an 
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anticlotting agent are metabolized by enzymes which show genetic variants which are 
functionally important.   
Genetic variants are not only known for CYP enzymes but also for enzymes mediating 
conjugation reactions and for transporters. Thus, the kinetics of the drug and its clearance 
depend on the activity of the genetically determined enzyme expression. Thus, the right 
dose for the individual patient of these drugs depends on his/her genetic makeup. 
It is clear that the next generation of doctors will increasingly rely on pharmacogenetics to 
guide therapy.  
 
 
Prof. Jacques Haiech 
Position Professor 
Organisation University of Strasbourg 
Department School of Pharmacy 
Town Illkirch 
Country France 
E-mail haiech@unistra.fr 
Biography Prof. Jacques Haiech graduated in Mathematics from Orsay University, France and has 
obtained his PhD in Biochemistry in Montpellier with research in the fields of Calcium 
signaling. After a post-doctoral appointment at National Cancer Institute (NIH, Bethesda), 
Jacques has been recruited at CNRS (Centre national de la recherche scientifique, 
France). He headed the department of biochemistry and pharmacology and then moved to 
Marseilles in 1987. He was also visiting professor at the Vanderbilt University and then at 
the Northwestern University (Chicago, Michigan). He became full professor at the university 
of Marseille-Luminy in 1991 and moved to Strasbourg university in 1987 where he 
developed the first academic screening platform and headed a research institute until 2005 
(Biotecthnology and Therapeutic Innovations). 
He has been the executive director of the French genomic program at the ministry of 
research (1999-2003). He is now vice-president of the scientific council of ARIIS (the 
Alliance for research and innovation of health industries) in France and scientific deputy in 
the new French evaluation agency (AERES). 
Jacques has published more than 150 papers in peer-reviews journals that have received 
more than 6000 citations. 
He has developed several training programs in synthetic biology in Strasbourg and Paris for 
students in pharmacy and in school of engineers. 
Abstract Education and Personalized Medicine: The Challenge 
In this presentation, we will describe a general frame in order to anticipate the evolution of 
life sciences from a descriptive science to a predictive science with the emergence of 
systems biology and synthetic biology. 
We will open a debate on the impact of such new paradigms on health research and 
discovery (from new therapeutic innovations to personalized medicine) and the 
consequences on the education of health professionals.  
Ongoing pilots of innovative training programs in France will be described in order to 
benchmark with other pedagogical initiatives in Europe. 
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Dr Adriano Henney 
Position Director 
Organisation University of Heidelberg 
Town Heidelberg 
Country Germany 
E-mail adriano.henney@virtual-liver.de 
Biography Dr Henney obtained a PhD in Medicine and has 23 years’ research experience in 
cardiovascular disease in laboratories in London, Cambridge and Oxford. His interests 
have focused predominantly on atherosclerosis, with studies ranging from pathology, 
through molecular and cellular biology to molecular genetics. In 1997, he was recruited by 
Zeneca Pharmaceuticals from a Senior Fellowship position leading his own molecular 
genetics group in Oxford, to lead the exploration of new therapeutic approaches in 
atherosclerosis, specifically focusing on his research interests in vascular biology. 
Following the merger with Astra, Dr Henney moved within the newly formed company, 
AstraZeneca, to a position of Global Programme Manager responsible for prototyping 
strategic improvements to the company’s approaches to pharmaceutical target 
identification, and the reduction of attrition in early development. This involved directing 
activities both across research sites and across functional project teams in the US, Sweden 
and the UK. The work undertaken in this Programme resulted in the creation in July 2003 of 
an entirely new multidisciplinary department that focused on pathway mapping, modelling 
and simulation. With personnel based in the UK and US, and global project interactions 
across all therapy areas, the work of this department supported drug projects across 
Research and Development. Under his leadership, the department evolved to establish the 
practice of Systems Biology that, together with strong relationships with key academic 
centres and biotechs, prototyped the application of mechanistic disease modelling 
approaches to the discovery of innovative new medicines. Since leaving AstraZeneca in 
2009, Dr Henney has continued his interest in Systems Biology through his company, 
Obsidian Biomedical Consulting Ltd., helping academics to work more closely with industry. 
In April 2010, Dr Henney was invited to direct a, new major German national initiative in 
Systems Biology: the Virtual Liver Network. 
 
 
Prof. Manfred Jung 
Position Full Professor 
Organisation University of Freiburg 
Department Institute of Pharm. Sci - FRIAS 
Town Freiburg 
Country Germany 
E-mail manfred.jung@pharmazie.uni-freiburg.de 
Biography Manfred Jung (1966) was educated at the Universities of Marburg, Ottawa and Münster 
(Ph.D. with Prof. Dr. Wolfang Hanefeld, postdoctoral studies with Prof. Dr. Tony Durst, 
habilitation association with Prof. Dr. Bernard Unterhalt). He is currently Professor for 
Pharmaceutical Chemistry at the University of Freiburg. He has published over 100 papers, 
holds two patents and has received the joint Medicinal Chemistry Award of the Medicinal 
Chemistry groups of the German Pharmaceutical Society and German Chemical Society. 
19 
 
His research focus is Chemical Epigenetics. The group is active in the synthesis of 
inhibitors of epigenetically active enzymes, both as biological tools and potential drugs. 
Another strong methodological focus is the development of screening assays for enzymes 
and their application in the search for new epigenetic modulators. 
Abstract Epigenetics is defined as heritable changes in the phenotype without changes in the 
genetic code. The development of a complex organism requires that only a selected 
number of genes from the whole genome is expressed according to the cell type. The 
maintenance of such expression profiles upon cell division is governed by epigenetic 
processes such as DNA methylation and histone modifications. If we study these 
mechanisms we may understand their role in human disease and find new ways for 
treatment and stratification of patients in personalized medicine. This lecture will provide an 
overview of epigenetics and available epigenetic drugs. The work of our group both in the 
direction of drug discovery but also in the use of assays for detecting the activity of 
epigenetic enzymes in cells and patient samples will be presented. 
 
Prof. Jonathan Knowles 
Position Professor  
Organisation Ecole Polytechnique Fédérale de Lausanne/ Institute for Molecular Medicine Finland 
Town Lausanne  
Country Switzerland  
E-mail jonathan.k.c.knowles@gmail.com  
Biography Dr. Knowles was Head of Group Research and Member of the Executive Committee at 
Roche up to the end of 2009. He was a member of the Genentech Board for the last 12 
years and a member of the Chugai Board for seven years. Dr. Knowles was also the 
chairman of the Corporate Governance Committee of Genentech. Prior to this he served as 
Director of the Glaxo Institute in Geneva for 10 years and as head of European Research 
for Glaxo Wellcome. 
Jonathan Knowles holds a Distinguished Professorship in Personalized medicine at FIMM 
(Institute for Molecular Medicine Finland) at the University of Helsinki, was recently 
appointed Professor of Translational Medicine at EPFL in Switzerland, and has been 
appointed to a Visiting chair at the University of Oxford. In addition, he is a Member of the 
European Molecular Biology Organization and a Visiting Fellow of Pembroke College 
Cambridge. In 2011, Jonathan Knowles was appointed as a Trustee of Cancer Research 
UK, one of the world’s leading Cancer Research Organisations. 
Abstract The Molecular Personalization of Medicine: Future vision or immediate necessity? 
The application of molecular “omics” to address medical questions has dramatically 
increased in recent years and is revolutionizing our understanding of the molecular 
pathology and interrelationships between different human conditions. Despite this, the 
number of new therapies made available each year is in relative decline and clinical 
practice is slow in adopting the new molecular diagnostics.  
There is a growing need to reclassify human disease through new more specific molecular 
criteria to allow the creation of new treatments and therapies. Equally, there is a critical 
need to apply today's knowledge especially in the treatment of cancer patients.  
The molecular personalization of Medicine is thus an immediate necessity for both basic 
research into disease mechanisms and for the treatment of patients today. The rational for 
these statements will be provided and strategies for rapid and transformational 
implementation will be outlined. 
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Prof. Hans Lehrach 
Position Director 
Organisation Max Planck Istitute for Molecular Genetics 
Department Vertebrate Genomics 
Town Berlin 
Country Germany 
E-mail lehrach@molgen.mpg.de 
Biography Hans Lehrach is one of Germany’s foremost molecular biologists. He obtained his Ph.D. at 
the Max Planck Institute for Experimental Medicine and the MPI for Biophysical Chemistry 
in 1974. He moved on to Harvard University, Boston (1974-1978) for a postdoc and then 
became group leader at EMBL, Heidelberg (1978-1987). At the Imperial Cancer Research 
Fund, London (1987-1994) he was head of the Genome Analysis Department. He then 
returned to Germany to become Director at the MPI for Molecular Genetics (since 1994). 
His scientific achievements are many. Highlights include his key involvement in several 
genome sequencing projects, such as the human, rat, and Schizosaccharomyces. His 
group was part of the team which identified the Huntington’s disease gene. Dr. Lehrach 
also performed key work on technologies such as protein microarrays, protein interactome 
analysis, yeast artificial chromosomes and RNAseq.  
Dr. Lehrach has co-founded several biotechnology companies such as Sequana 
Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech, Atlas Biolabs, and Alacris 
Theranostics. 
Abstract The Future of Medicine 
The solution of many medically important problems depends primarily on being able to 
predict the behaviour of complex networks (e.g. the biological networks acting within a 
tumor, but also in the other tissues of the patient) under complex disturbances (e.g. a 
particular therapy). Decades of molecular cancer research, but also the recent genome 
revolution, have however still not been able to provide this urgently needed power to 
predict.  
We are currently sequencing the genome and transcriptome of the tumor and the genome 
of the patient for individual cancer patients, as the basis of a ‘virtual patient’ models, which 
can then be used to predict effect and side effects of specific therapies on the individual 
patient (www.treat1000.org). In addition, we have proposed IT Future of Medicine (ITFoM), 
www.ITFoM.eu), with the goal to develop integrated molecular/physiological/anatomical 
models of every individual in the health care system, on the basis of –omics (genomics, 
epigenomics, transcriptomics, proteomics, metabolomics, metagenomics etc), imaging and 
sensor data, as the basis of a new, data rich, computation based individualised medicine of 
the future. 
 
 
Prof. Soulla Louca 
Position Associate Professor 
Organisation University of Nicosia 
Department Management & MIS 
Town Nicosia 
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Country Cyprus 
E-mail louca.s@unic.ac.cy 
Biography Soulla Louca received her Ph.D. in Computer Science in 1994 from Illinois Institute of 
Technology in Chicago. Prior to that, she had received a B.A in Computer Science and 
Mathematics and a M.Sc. in Computer Science from Kalamazoo College and Western 
Michigan University respectively.  She has participated and coordinated numerous projects 
including National Science Foundation (NSF-USA), Research Promotion Foundation (RPF-
Cyprus) and European; has served as a reviewer for various international 
conferences/journals as well as an ICT expert for the European Commission.  Her research 
interests include socio-economic aspects of Green ICT, e-learning, social integration and 
digital divide, and e-business Since June 2008; she is the Chair of the Domain Committee 
for Information Communication Technologies for COST. Dr Louca is an Associate 
Professor at the University of Nicosia in the Department of Management and Management 
Information Systems. 
Abstract Why another Conference on Personalised Medicine? 
The major obstacles for making personalized medicine available to patients requires basic, 
translational, and also regulatory science, especially in the areas of ethical, legal and social 
issues.  The vision of a good healthcare system in which the patient care is consistently 
augmented through the use of information on the individual patient’s genomes and their 
downstream products requires the exploration of strategic relationships among all 
interesting parties and constellation thinking for proposing new ways in the diagnosis and 
therapy of diseases integrated with a planned trans-disciplinary scientific approach 
involving various disciplines such as life sciences, mathematics, physics, chemistry and 
ICT.  Connecting high-quality trans-disciplinary scientists through programs such as COST 
can support capacity building, and increase the impact of personalized medicine research 
on regulatory bodies, decision makers, pharmaceutical, insurance companies and the 
paying public. Such group efforts could enable breakthrough scientific developments 
leading to new concepts and products and thereby contribute to the strengthening of 
Europe’s research and innovation capacity while reforming the healthcare system. 
 
 Dr Mira Marcus-Kalish 
Position Director, International Research 
Organisation Tel Aviv University 
Department The Interdisciplinary Center For Technology Analysis and Forcast (ICTAF) 
Town Tel Aviv 
Country Israel 
E-mail miram@post.tau.ac.il 
Biography Dr. Mira Marcus-Kalish is currently a Senior Research Fellow at ICTAF – Interdisciplinary 
Center for Technological Analysis and Forecasting, and the director for international 
research affairs at Tel Aviv University. Her main areas of interest are mathematical 
modelling, data Analysis, converging technologies and data mining (mainly a targeted rule 
discovery tool for Bio-Medicine). Recent projects focused on personalized skin treatments, 
rehabilitation of the discrete sensory motor learning function, cerebellar motor learning, 
protein- protein interactions, drug toxicity analysis, learning machine systems, smart 
sensors for tackling oil spill, multilevel multisource data mining applied to neurology, etc.  
Mira Marcus-Kalish holds a Ph.D in operations research from the Technion, Haifa, where 
she developed a computerized E.C.G. diagnosis system. She did her post doctorate 
training at Harvard University, at the MBCRR laboratory (Molecular Biology Computer 
Research and Resource) and the Dana Farber Cancer Institute. Her B.Sc. is in Statistics 
and Biology from the Hebrew University in Jerusalem. 
Coming back to Israel, she joined the Tel-Aviv University Business School, focusing on 
Medical informatics and management, than moved to the Weizmann Institute working with 
Prof. Ephraim Katzir mainly on protein interactions. She was involved at the private 
business enterprise and served as the scientific advisor and later as the head of the 
Enterprise Marketing Department in IBM Israel. Dr. Kalish is involved in many EU 
framework projects: ReNaChip, SkinTreat, EpoCan, HBR, etc and was the joint research 
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work package leader in the Nano2Life NoE (Network of Excellence). 
Abstract Simultaneous Systematic Analysis approach, an essential enabler to preventive, 
predictive and personalized medicine. 
The revolutionary trends in scientific health care research have provided new and profound 
insights into the human body functioning in its surroundings enabling various degrees of 
sensitivity. 
The goal is to enable the “whole approach” - a simultaneous systematic analysis providing 
the broad insight on various phenomena and disease through identifying all relevant factors 
at the micro as well as macro environment. The simultaneous sharing and converged 
research of the body physical mechanisms combined with mental, cultural, community and 
environmental factors are the enabler for reliable and responsible personalized medicine. 
This approach will require the endeavour of interdisciplinary research, new philosophical 
approach as well as new innovative analysis tools specially developed to utilize all acquired 
knowledge translated into the optimum practice of preventive, predictive and personalized 
medicine. 
The coupling of computer sciences, complexity theory, non linear dynamics and logic 
theory lead the development of learning machines revealing the underlying rules in specific 
phenomena and various disease that improves it accuracy and prediction tools while 
usage. 
These tools are crucial for medical research and especially for clinical trials, enabling the 
analysis of small and well defined groups towards responsible treatment. 
Our patented Data Mining rule discovery tool is just one example, specially developed to 
relate to the individual within the natural and artificial surroundings as one complex 
functioning system. The tool enables multilevel, multisource data analysis (images, 
numeric, signals, categorical, descriptive data, etc) while relating to the whole data set as is 
– no normalization, manipulation or data neglected. Further more the tool minimizes over- 
fitting and identifies the unexpected rules and cases which are crucial for reliable clinical 
trials. It was already applied successfully to autoimmune diseases, degenerative diseases, 
structural biology, drug development, personalized skin treatment, neuronal biomarkers, 
etc.  
It is time to shift the paradigm in research and development, join all forces – knowledge, 
information and tools to enable the new era of healthcare treatment for the well being of all 
 
 Prof. Emmanuel Mikros 
Position Professor 
Organisation University of Athens 
Department Pharmacy 
Town Zografou 
Country Greece 
E-mail mikros@pharm.uoa.gr 
Biography Emmanuel Mikros, Chemist, Ph.D. is Professor in Pharmaceutical Chemistry University of 
Athens. He obtained his Ph.D in Chemistry from Universite Paris-Sud (Paris XI) in 1988 
and then he joined University of Athens. Research Fellow at the Institut für Chemie 
Medizinische Universität zu Lübeck, Germany, with Prof. T. Peters at 1996 and at the 
Laboratoire  Ingenierie Moleculaire, INRA, Centre de Recherches de Nantes, France with 
Dr. S. Perez (1993 and 1994). He was awarded the DAAD (Germany, 1996) and Marie 
Curie (European 1994) Fellowships. He is an author of 70 peer reviewed scientific 
publications (1000 citations, h-factor 18). He has participated in over 20 research and 
educational projects funded by National and EU organisms, the most recent are : FP7- 
Research Potential-2007, FP7-PEOPLE-Industry-Academia Partnerships And Pathways-
2008 Marie Curie Actions, FP7- Knowledge Based Bio-Economy-2009-3-1-04 He is 
member of several national and international scientific societies (EFMC, ACS) and vice 
president of Hellenic Society of Medicinal Chemistry. Invited speeker in more than 20 
international meetings, he has also participated in the organising committee of 4 
international and national scientific congresses. Prof. Mikros leads a research group 
focused on NMR spectroscopy, NMR based Metabonomics Structure elucidation of 
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biomolecules, natural products and drugs, as well as Molecular Modeling docking-scoring 
calculations, in silico screening and Structure Activity Relationships.  The group is currently 
involved in several metabonomic projects in collaboration with internal and external 
partners covering areas like characterisation of metabolic responses to chemical exposure 
hepatotoxicity, cardiotoxicity), disease diagnosis (inborn error of metabolism, cancer), 
sports biochemistry and plant metabolic profiling. Important experience has been also 
gained through the systematic study of receptors like Kinases (CDKs, GSK3, DYRK, CK1), 
Nuclear Receptors (ERα, ERβ, AR) and membrane transporters, concerning their 
interaction with small molecules using Molecular Modeling calculations. Specific docking 
calculation protocols and scoring functions have been established and used in order to 
design new molecules with desired biological activity. Supervisor of 4 Ph.D. theses. He set 
up and he is responsible of the NMR facility of the Faculty of Pharmacy University of 
Athens.  
Abstract Metabonomics represents a holistic, hypothesis-free, approach to the study of metabolic 
responses to various stimuli through powerful data acquisition and advanced data 
processing techniques. This approach aims to the highthroughput analysis of the metabolic 
profiles of biofluids, tissues, extracts etc taking advantage of the degree of inherent 
biochemical similarities between samples. 
NMR spectroscopy and/or MS have been utilized as main analytical platforms in 
Metabonomics studies. The application of NMR and MS to biological materials allows the 
simultaneous detection, identification, and quantitation of a variety of low-molecular-weight 
metabolites from a range of intermediate metabolic pathways. This is possible in 
combination with the newly emerging methods for automated data reduction and pattern 
recognition techniques (multivariate chemometric analysis) leading to the efficient 
exploitation of complex spectral profiles. 
Metabolic profiling and understanding metabolic fluctuations could be translated into clinical 
tool with applications in personalized medicine. In this aspect administration of drugs 
should be adjusted to achieve maximum effectiveness and avoid side effects which may be 
different for each organization. One of the approaches is the understanding of genetic 
differences between individuals and the correlation with the response to drug therapies 
both in the therapeutic effect and to the side effects, known as pharmacogenomics. The 
relationships between the individual genomic and phenotypic variation in response to drug 
treatment have not yet fully understood, and it is unlikely that genetic information is not able 
to guide personalized drug therapy. The metabolic phenotype or metabotype provides a 
holistic approach to the biological system being the product of genetic and environmental 
contributions (diet, lifestyle, intestinal flora, etc.), ie a particular set different for each body. 
Very recently, an alternative approach to understanding the variability of responses to 
pharmacotherapy has been developed, called Pharmacometabonmics. The new approach 
can be used to predict the metabolism, toxicity and general organization of a response to 
medication based solely on analysis and modeling of metabolic profiles before treatment 
(Clayton TA, et al. Nature 440, 1073-1077, 2006). 
 
 Dr Paul Mitcheson  
Position Senior Lecturer (Associate Professor) 
Organisation Imperial College London 
Department Electrical and Electronic Eng 
Town London 
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E-mail paul.mitcheson@imperial.ac.uk 
Biography Paul. D Mitcheson received the M.Eng. degree in electrical and electronic engineering and 
the Ph.D. degree from Imperial College London, U.K., in 2001 and 2005 respectively.  He 
became a lecturer (Assistant Professor) at Imperial College in 2006 and is currently a 
senior lecturer (Associate Professor) in the Control and Power Research Group, Electrical 
and Electronic Engineering Department and Imperial College London.  He has research 
interests in energy harvesting devices, in particular the power processing requirements for 
harvester powered systems and devices powered from human body motion. 
Abstract Energy harvesting in health care applications 
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The supply of power to worn or body-implanted medical devices remains a barrier to their 
ease of use and their uptake.  In this talk I will discuss the possibilities for powering devices 
from the human body, including movement, thermal and RF energy harvesters.  The issue 
of wireless powering of devices using near field inductive coupling and acoustic coupling 
will also be covered.  Experimental details of prototype power sources targeted to human 
body worn applications will be discussed. 
 
 Dr Christos A. Nicolaou 
Position Principal Research Scientist 
Organisation Eli Lilly and Co 
Department Global Scientific Informatics 
Town Indianapolis 
Country United States 
E-mail christodoulos.nicolaou@gmail.com 
Abstract Evolving Approaches to Drug Selectivity and Designed Polypharmacology 
Modern drug discovery focuses for the most part on the identification of ‘magic bullets’, i.e. 
perfect drugs that cure a disease in the general population with no, or very low, danger of 
side effects. The specific aim of the drug discovery process is to identify molecules that 
selectively bind and interact with a specific biological receptor implicated in the outbreak of 
a disease, and cause certain desired behaviour. In addition, a drug must also exhibit 
satisfactory pharmacokinetics and toxicity properties to ensure that it moves appropriately 
in the living organism to be treated, reaches the region of the target without causing side 
effects and binds selectively to the pharmaceutical target.  
The drugs currently available to patients are a testimony to the success of this paradigm. 
However, the decreasing numbers of new drugs approved as well as a number of drug 
recalls are an indication to the paradigm’s limitations. Numerous recent advances in our 
understanding of human biology and disease occurrence pave the way for a new, 
complementary approach that takes into account pharmaceutical target relations to design 
more selective drugs and drugs which exhibit appropriate polypharmacology. This 
presentation will initially review the steps of the modern drug discovery process and 
elaborate on some of its challenges. The advances in the new field of pharmacogenomics 
will be described and a brief overview of new strategies for designing drugs with increased 
selectivity will be provided. The later section of the presentation will focus on the potential 
for multi-target drugs and the evolving drug discovery paradigm of designed 
polypharmacology.  
 
 
Prof. K.C. Nicolaou 
Position Professor & Chairman 
Organisation The Scripps Research Institute 
Department Chemistry 
Town La Jolla, California 
Country United States 
E-mail kcn@scripps.edu 
Biography K.C. Nicolaou was born on July 5, 1946 in Cyprus.  In 1964, he emigrated from Cyprus to 
England. His studies in chemistry were completed at the University of London (B.Sc., 1969, 
Bedford College, First Class Honors; Ph.D. 1972, University College, with Profs. F. 
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Sondheimer and P.J. Garratt). In 1972, he moved to the USA and completed postdoctoral 
appointments at Columbia University (1972–1973, Prof. T.J. Katz) and Harvard University 
(1973–1976, Prof. E.J. Corey), after which he joined the faculty at the University of 
Pennsylvania, and rose to the rank of Rhodes-Thompson Professor. In 1989, he accepted 
joint appointments at the University of California, San Diego, where he is Distinguished 
Professor of Chemistry, and The Scripps Research Institute, where he is the department 
chairman and holds the Darlene Shiley Chair in Chemistry and Aline. W. and L. S. Skaggs 
Professorship in Chemical Biology. 
For his scientific work, Professor Nicolaou has received numerous awards and honors, 
including the ACS Linus Pauling Medal (1996), RSC Centenary Medal (2000–2001), 
Tetrahedron Prize for Creativity in Organic Chemistry (2002), ACS A. C. Cope Award 
(2005), and Benjamin Franklin Medal in Chemistry (2011). 
Nicolaou is a Fellow of the American Academy of Arts and Sciences (1993), Member of the 
National Academy of Sciences (USA, 1996), Foreign Member of the Academy of Athens 
(Greece, 2001), Member of the German Academy of Sciences Leopoldina (2009), and 
Member of the American Philosophical Society (2011), and holds 10 honorary degrees from 
universities around the world. 
He is the author or co-author of over 735 scientific articles, reviews, and book chapters, 66 
patents, and 5 books, including the popular Classics in Total Synthesis (Vols. 1–III) series 
with Wiley-VCH, and Molecules That Changed the World, co-authored with Tamsyn 
Montagnon (2008, Wiley-VCH). His dedication to chemical education is evidenced by his 
training of more than 400 graduate students and postdoctoral fellows. 
Abstract Molecules that Changed the World 
This lecture, based on the recent book by Nicolaou and Montagnon1, will expound on our 
learned knowledge of some of Nature’s most intriguing molecules and the ability of Man to 
discover, synthesize, modify and use them to our advantage in what was not formerly 
envisioned. Through the development of the theme, it is hoped that one will also discover 
just how profound the impact of chemistry is in our lives. The lecture will also explore some 
of the most exciting frontiers in modern science and medicine, and the opportunities they 
present to young students for future careers. Illustrated in a colorful style, this presentation 
will aim to provide insights about the role of chemistry in society in general and how 
chemical synthesis, the art and science of constructing natural and designed molecules, in 
particular, shaped and continues to shape our world. Indeed, the lecture will touch upon 
fascinating tales about molecules and their presence in, among many items, high tech 
materials, foods, vitamins, nutritional supplements, and above all, medicines. The history of 
total synthesis, the flagship of chemical synthesis, as unraveled within the scope of this 
lecture will hopefully serve to underscore how admirably chemical synthesis enabled and 
facilitated world-shaping innovations in medicine since its inception in 1828 by Friedrich 
Wöhler. 
1 Molecules That Changed The World, by K.C. Nicolaou and T. Montagnon, Wiley-VCH, 2008. 
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Biography Irene Norstedt has been working with various aspects of European Life Sciences research 
at the European Commission since 1996. She is currently Deputy Head of Unit for the 
Personalised Medicine Unit in the Health Research Directorate in DG Research and 
Innovation. Before that she was one of the key drivers for setting up the Innovative 
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Medicines Initiative (IMI), a public private partnership between the EC and the 
Pharmaceutical industry. Previous responsibilities at the EC have primarily focussed on 
Small and Medium size Enterprises and industry aspects of biotechnology and health 
research at European level. Before starting her job in Brussels she worked for Biscoe AB in 
Uppsala, Sweden. There she had several positions including Business Development for the 
Drug Discovery and Food Analysis areas and Technical Services Manager. She has also 
worked as Assistant Technical Attaché at the Swedish Embassy in London. 
Abstract Personalised Medicine Research at European level 
Personalized medicine is a novel approach to healthcare based on a better molecular 
understanding of health and disease. Some personalized medicine approaches have begun 
to show results but much research is still needed to progress the area.  
The European Commission (EC) has allocated some €900 million to personalized 
medicine, enabling research over the latest 5-year period via the Health Theme of the 
Seventh EU Framework Programme for Research and Technological Development (FP7).  
To gain a better understanding of key research needs in the area, the Personalised 
Medicine Unit of the ECs Health Research Directorate organized several workshops and a 
large-scale conference during the period between 2010–2011.  
The key research challenges identified can be grouped around four main themes:  
Breaking barriers and speaking the same language: facilitating interaction between different 
disciplines from basic to clinical research by creating appropriate interfaces for 
collaboration and discussion among stakeholders.  
Generating knowledge and developing the right tools: adapting research tools to clinical 
use by developing common standards for data collection and linking clinical data with 
molecular profiles, for example, translating ’omics research into clinical application.  
Translation to medical applications: finding new approaches for identification, qualification 
and clinical validation of all types of biomarkers; improving the use of biomarkers for better 
use of existing therapies and adaptive clinical trial methodologies.  
Economic aspects: proving the economic viability and positive patient benefits of 
personalized medicine and developing methodologies for health technology assessments 
and for comparative cost–effectiveness studies on personalized medicine approaches. 
The EC will continue to invest in research fostering the development of personalized 
medicine approaches, both through its current FP7 Health Research Theme in 2012 and 
2013 as well as in its next funding program for research and innovation – Horizon 2020.  
 
 
Dr Morag Park  
Position Scientific Director  
Organisation CIHR (Canadian Institutes of Health Research) 
Department Institute of Cancer Research 
Town Montreal 
Country Canada 
E-mail mpark.ic-icr@mcgill.ca 
Biography Dr. Morag Park received her PhD in 1983 at Glasgow University, Scotland. For her 
postdoctoral studies she joined the lab of Dr. George Vande Woude at the National Institute 
of Cancer, US where she identified the Met receptor tyrosine kinase. She joined McGill 
University in 1988 where she is now a Professor in the Departments of Oncology, 
Biochemistry and Medicine. In addition, she holds the Diane and Sal Guerrera Chair in 
Cancer Genetics. Dr. Park is currently the Scientific Director of the CIHR Institute of Cancer 
Research. She has also served as Director of the McGill Molecular Oncology Group and 
joint head of the Cancer Axis at the McGill University Health Centre, and as a member of 
the Fonds de la Recherche en Santé du Québec, Réseau Cancer. She has a long standing 
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interest in the molecular mechanisms of cancer. Dr. Park has published over 100 papers in 
peer-reviewed journals. She is recognized for her work on the Met receptor tyrosine kinase 
and signaling pathways that regulate cell migration and invasion in cancer. A major thrust of 
her work now focuses on human breast cancer and the importance of the tumour 
microenvironment to the outcome of this disease. Her work has been recognized with 
numerous awards including becoming a Fellow of the Royal Society of Canada 
Abstract Personalised Medicine Research and Canada 
The overall goal of the Canadian Institutes of Health Research Personalised Medicine 
Signature Initiative is to support translational research for the effective prevention, 
diagnosis, and treatment of complex diseases with the ultimate goal of stratifying patients 
based on their susceptibility to a disease or their response to a specific treatment; and to 
promote health services research to effectively integrate such innovations into policy and 
practice for the benefit of Canadians. 
 
 
Dr Cristiana Pavlidou 
Position Collaborator  
Organisation GOLDEN HELIX Institute of Biomedical Research 
Town Athens  
Country Greece  
E-mail chpavlidou@upatras.gr 
Biography Dr. Christiana Pavlidou has completed her Bachelor Degree in Dietology and Applied 
Dietetics , receiving the tiltle of Dott.ssa  (Dr) as Nutritionist-Dietitian in 1998 concluding her 
thesis on the role of the Nutritional Counselling in Cystic Fibrosis Pediatric patients. 
Between 1998 and 1999 she was involved in one of the first research projects in the 
supplementation of EPA/DHA in Cystic Fibrosis Pediatric Patients in the Pediatric Clinic of 
the University of Naples Federico II.  In 2001 she received her MSc in Clinical Nutrition  
from the University of Surrey (Roehampton, London, UK) concluding a thesis project on the 
prevalence of body image dissatisfaction and eating disturbances among sports and non-
sports students. In addition, she completed the 2 parts in order to obtain an online diploma 
on the promotion of Science and Technology from the University of Ca’ Foscari, Venice 
Italy.  
She is now in the process of completing her PhD at the University of Patras, Greece on 
nutrigenomics with Dr. George Patrinos.  
She works as a freelance dietitian-nutritionist in a seaside suburb in Palaio Faliro in Athens, 
Greece and as a collaborator of the children’s private hospital ‘IASO Paidon’ in Marousi, 
Athens involved in the nutritional counseling and support of pediatric patients. 
In the previous years, she has collaborated with a private clinic in Athens and has 
previously worked (2004-2008) in the biscuit Industry Papadopoulou as a nutritionist 
consultant involved in marketing and R&D projects. Between 2008- 2011 she was the 
Scientific Director of Paideiatrofi by Epode programme for childhood obesity prevention 
currently running in Greece and also the Scientific Director of Nostus Communications and 
Events. During 2008-2010 she worked as a nutrition/dietetics professor in the IEK private 
schools for Chef (Le Monde) and Dietitians (Ippokrateios in 2010 only).  
She is a collaborator of the Golden Helix Institute of Biomedical Research 
(www.goldenhelix.org) involved in various research projects. 
She has presented many of the projects involved in many world and regional congresses 
and she holds scientific publications. 
Abstract Development of centralized National Genetics databases and their implications for 
personalized medicine 
National/Ethnic Mutation databases (NEMDBs) are increasingly becoming important tools 
for the documentation of genomic variations in various populations around the globe and as 
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such they assume an important role in the provision of genetic services. Presently, the 
adoption of NEMDBs is not uniform and varies among different populations and national 
healthcare systems. Also, development of these NEMDBs should conform to certain 
guidelines and recommendations that would assist genetic variation data capture in 
developing countries to ensure a comprehensive worldwide data collection and better 
provision of healthcare services. We have previously reported the development of the 
ETHNOS software, on which several NEMDBs have been developed [Patrinos et al., Hum 
Mutat, 2005; van Baal et al., Hum Genomics, 2010], which has contributed not only to the 
establishment of similar databases for different populations but also to database content 
uniformity, as more than half of the available NEMDBs are based on this software. The 
NEMDB notion has also been further expanded, yielding either a worldwide central 
repository for allele frequency data or a data warehouse of anonymous individual-level 
genetic data. One such worldwide central allele frequency repository, where frequency of 
genetic variants that relate to a phenotypic alteration, namely inherited disease or variable 
drug response, will be deposited is FINDbase (www.findbase.org; 12) has already been 
established along these lines and documents a substantial amount of genetic data and 
allele frequencies of pathogenic mutations [van Baal et al., Nucleic Acids Res, 2007; 
Georgitsi et al., Nucleic Acids Res, 2011] and pharmacogenetically relevant SNPs 
[Georgitsi et al., Pharmacogenomics, 2011]. Apart from this application, collection of clinical 
genetic information on patients with particular genetic diseases, the investigation of a 
family's clinical history and genotype-phenotype correlations are also of utmost importance. 
The first efforts in that direction have begun to make an appearance. In particular, a 
prototype software, allowing an individual’s genetic profile to be stored has been developed 
(Gkantouna, Tzimas, Patrinos, unpublished), so that this information can only be retrieved 
by the patient and his/her physician. Such database, currently under development, would 
allow patients to securely store all his or her genetic information and related phenotype, 
hence contributing decisively to customized medical treatment, better diagnosis of 
hereditary diseases of patients, unambiguous personal identification. Also, having data in a 
structured format, the end-user can now easily statistically analyse them and draw useful 
conclusions. 
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Biography Roland Pochet was born in Brussels. He studied Chemistry, did a PhD in Biochemistry at 
Université Libre de Bruxelles (ULB), a postdoctorate as EMBO fellow at the Hebrew 
University of Jerusalem (Dpt of Experimental Medicine). He spent 6 months at Vanderbilt 
University (Nashville) as NATO fellow. He is Professor of cell biology at the Faculty of 
Medicine ULB, General secretary of the Belgian Brain Council, chair of the Biomedicine and 
Molecular Biosciences Domain Committee of COST and member of EDAB (European 
DANA Alliance for the Brain). He is head of the ALS (Amyotrophic Lateral Sclerosis) unit at 
the Histology, Neuroanatomy and Neuropathology laboratory (ULB) and focuse his 
research on cell transplantation of stem cells in an ALS animal model. 
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Prof. Barbara Prainsack 
Position Professor of Sociology and Politics of Bioscience 
Organisation Brunel University 
Department Sociology and Communications 
Town Uxbridge 
Country United Kingdom 
E-mail barbara.prainsack@brunel.ac.uk 
Biography Barbara Prainsack was awarded her PhD in Political Science at the University of Vienna, 
Austria, where she worked and published on issues of governmentality. She is now 
Professor of Sociology and Politics of Bioscience at the Centre for Biomedicine & Society 
(CBAS), Dept. of Sociology and Communications, Brunel University. She has published 
widely on the societal, ethical, and regulatory dimensions of biomedicine and bioscience 
(genetic and genomic science and technologies in particular). She is a member of the 
Austrian National Bioethics Commission, and co-chair of the Scientific Committee of the 
ESF's Forward Look on Personalised Medicine. From January to July 2011, she was 
AHRC/ESRC Fellow for the project ‘Solidarity as a Core Value in Bioethics’ at the Nuffield 
Council on Bioethics in London, UK. 
Abstract Personalised Medicine and the Citizen: A Participatory Turn in Health? 
Recently, a lot of attention has been paid to the topic of patient and citizen empowerment in 
the health domain. But what citizen empowerment in health and medicine mean in practical 
terms, and how does it impact on how healthcare is organised, delivered, accessed, 
“consumed”, evaluated, and financed? What does it mean for the context of Personalised 
Medicine specifically, with its inherent focus on rendering prevention, diagnosis, treatment, 
and monitoring more “tailored” to individuals? Moreover, now that we are seeing citizens 
organising their own trials, publishing papers, and crowd-sourcing treatment decisions to 
wider audiences instead of turning to traditional experts, has citizen empowerment perhaps 
already transcended the concepts and issues dominating our debates? Finally, does citizen 
empowerment in the health domain catalyse the development of Personalised Medicine, or 
is it in any way detrimental to the endeavour? 
 
Dr Kamran Sayrafian 
Position Program Lead 
Organisation National Institute of Standards and Technology (NIST) 
Department Information Technology Laboratory 
Town Gaithersburg 
Country United States  
E-mail ksayrafian@nist.gov 
Biography Dr. Kamran Sayrafian is a program manager at the Information Technology Laboratory of 
the National Institute of Standards and Technology (NIST) located in Gaithersburg, 
Maryland. He leads several strategic projects that are focused on Pervasive healthcare 
technologies. NIST is actively pursuing the standards and measurement research 
necessary to achieve the goal of improving healthcare delivery through information 
technology. Dr. Sayrafian is an actively with several standard organization committees such 
30 
 
as IEEE802.15.6 international standardization on medical body area networks and ASTM 
2761. Prior to joining NIST, he was the cofounder of Zagros Networks, Inc. a fabless 
semiconductor company based in Rockville, Maryland where he served as President and 
senior member of the architecture team. He is the co-inventor/inventor of four U.S. patents. 
He has served as invited member of technical program committee and co-chair of many 
international conferences and workshops. His research interests include medical body area 
networks, mobile sensor networks and interference analysis/coexistence. He has published 
over 70 conference and journal papers, and book chapters in these areas. He was the 
recipient of the IEEE PIMRC 2009 & SENSORCOMM 2011 best paper awards. Dr. 
Sayrafian holds Ph.D., M.S. and B.S. degrees in Electrical & Computer Engineering from 
University of Maryland, Villanova University and Sharif University of Technology, 
respectively. He is a senior member of IEEE and an adjunct faculty of the University of 
Maryland. 
Abstract Personalised Health: An ICT Perspective 
Recent advances in miniature-sized microelectronics have created the opportunity to build 
ultra-small devices that can be implanted inside the human body. Adding communication 
capability to the limited computational power of such devices would allow the possibility of 
performing more complex functions by connecting multiple devices to each other or to 
external IT infrastructure. These radio-enabled medical devices can be used to 
continuously gather and process a variety of important health and/or physiological data 
wirelessly. They offer a revolutionary set of applications such as smart pills for precision 
drug delivery, intelligent endoscope capsules, and eye pressure sensing systems. The 
trend to create networking capability among many tiny devices is also expected to continue 
to molecular-sized sensors/actuators (i.e. nano-networking). In this presentation, an ICT 
perspective on challenges facing this trend is briefly discussed. 
 
 
Prof. Dieter Schinzer 
Position Professor for Organic Chemistry 
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Department Department of Chemistry 
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Biography Professor Schinzer holds a degree in Chemistry from the University of Marburg and 
obtained his doctoral degree from the University of Bonn. Since 1998 he has been teaching 
Chemistry at the University of Magdeburg in Germany and between 2002 and 2005 he was 
the dean of the Faculty of Process and Systems Engineering. Professor Schinzer is the 
chair of the CMST domain at COST and is also CEO of MOLISA GmbH since 2002. 
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Town Zagreb 
Country Croatia 
E-mail dina.simunic@fer.hr 
Biography Dr. Dina Šimunić is a full professor at University of Zagreb, Faculty of Electrical Engineering 
and Computing in Zagreb, Croatia. She graduated in 1995 from University of Technology in 
Graz, Austria. In 1997 she was a visiting professor in ”Wandel & Goltermann Research 
Laboratory" in Germany, as well as in "Motorola Inc", Florida Corporate Electromagnetics 
Laboratory, USA, where she worked on measurement techniques, later on applied in IEEE 
Standard. In 2003 she was a collaborator of USA FDA on scientific project of medical 
interference. Dr. Simunic is a IEEE Senior Member, and acts as a reviewer of IEEE 
Transactions on Microwave Theory and Techniques and on Biomedical Engineering and 
Bioelectromagnetics, journal JOSE and as a reviewer of many papers on various scientific 
conferences (e.g., IEEE on Electromagnetic Compatibility). She was a reviewer of Belgian 
and Dutch Government scientific projects, of the EU FP programs, as well as of COST-ICT 
and COST-TDP actions. She was acting as a main organizer of the data base in World 
Health Organization, for the service of International EMF Project from 2000 to 2009. From 
1997 to 2000 she acted as a vice-chair of COST 244: “Biomedical Effects of 
Electromagnetic Fields”. From 2001 to 2004 she served as vice chair of Croatian Council of 
Telecommunications. In 2006 she is elected the first time and re-confirmed in 2010 as vice-
chair of COST Domain Committee on Information and Communication Technologies (ICT). 
She is one of the proposers as well as a member of COST Trans-domain Committee. She 
is organizer of many workshops, symposia and round tables, as well as of special sessions. 
She has held numerous invited lectures, among others at ETH Zuerich, Switzerland in 1996 
and US Air Force, Brooks, USA in 1997). She is author or co-author of approximately 100 
publications in various journals and books, as well as her student text for wireless 
communications, entitled: “Microwave Communications Basics”. She is co-editor of the 
book “Towards Green ICT”, published in 2010. She is also editor-in-chief of the “Journal of 
Green Engineering”. Her research work comprises electromagnetic fields dosimetry, 
wireless communications theory and its various applications (e.g., in intelligent transport 
systems, body area networks, crisis management, security, green communications). She 
serves as Chair of the “Standards in Telecommunications” at Croatian Standardization 
Institute. 
 
Prof. Michael Strupp 
Position Head of the Dizziness Unit 
Organisation University Hospital Munich 
Department Neurology 
Town Munich 
Country Germany 
E-mail michael.strupp@med.uni-muenchen.de 
Biography Michael Strupp is Professor of Neurology and Clinical Neurophysiology at the University of 
Munich and Deputy Speaker of the new Integrated Center for Research and Treatment of 
Vertigo, Balance and Ocular Motor Disorders at the University of Munich. He studied 
medicine at the Technical University of Aachen, where he did his MD in the field of 
cardiophysiology. He then spent time doing basic neuroscience research involving patch-
clamp recordings with axons, muscle cells, glial cells and vestibular hair cells. Prof. 
Strupp’s particular area of interest is the pharmacotherapy of vestibular and ocular motor 
disorders. He is currently Editor-in-Chief of Frontiers in Neuro-otology and Join-Chief-Editor 
of the Journal of Neurology. He has received many clinical and scientific awards, including 
a “best teacher” award from the German Neurological Society, and has been a visiting 
professor at the University of Graz and the University of Prague. He is the author of more 
than 200 peer-reviewed papers and four books on vertigo, dizziness and ocular motor 
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disorders. He lives in Munich with his wife and four children. 
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Organisation University of Antwerp 
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Country Belgium 
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Biography Epigenomic profiling of phytochemical effects in cancer-inflammation and cardiovascular 
disease: challenges & pitfalls 
Abstract Epigenomic profiling of phytochemical effects in cancer-inflammation and 
cardiovascular disease: challenges & pitfalls 
Cancer and cardiovascular diseases remain one of the leading causes of death in Western 
society. Recently, epigenetic changes in DNA methylation patterns at CpG sites 
(epimutations) or deregulated chromatin states of genes and noncoding RNAs emerged as 
major governing factors in lifestyle diseases such as, cancer, obesity, diabetes and 
cardiovascular disease. Furthermore, various environmental factors such as nutrition, 
behavior, stress, and toxins remodel our epigenomes lifelong in a beneficial or detrimental 
way. Since epigenetic marks (epimutations) are reversible in contrast to genetic defects, 
various phytochemicals (soy, genistein, resveratrol, catechin, curcumin, cocoa flavanols) 
are currently evaluated for their ability to reverse adverse epigenetic marks in various 
diseased cell types (cancer cell, immune cell, endothelial cell). Although phytochemicals 
present in fruit and vegetables may help to protect against various inflammatory disease 
conditions, few protective effects have been firmly established, presumably because of 
inappropriate timing or dosing of diet exposure or due to confounding factors such as 
smoking and alcohol. We have applied genomewide MBD2-capture sequencing, Illumina 
450K CpG array, restriction enzyme methylation profiling, chromatin accessibility assays, 
cofactor profiling and CpG pyrosequencing in cancer cells or blood samples exposed to 
physiological concentrations of phytochemicals in cell culture or in diet interventions 
studies. Correlation of methylome profiles with gene expression data reveal complex 
epigenetic control mechanisms which may attenuate or interfere with disease progression. 
Challenges and pitfalls will be discussed of different platforms with respect to data analysis, 
normalization, interpretation and biological significance. 
 
Mr Albrecht von Müller 
Position Director 
Organisation Parmenides Foundation 
Town Pullach im Isartal 
Country Germany 
E-mail albrecht.von.mueller@parmenides-foundation.org 
Biography Albrecht von Müller is director of the Parmenides Center for the Study of Thinking. He 
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teaches philosophy at the Ludwig Maximilians University of Munich (LMU) and theory of 
thinking in an international master`s program on advanced complexity management, 
organized by SISSA (International School for Advanced Studies, Trieste). His two main fields 
of research are the concept of time and the phenomenon of thinking. In addition, Mr von 
Müller is interested also in the practical application of the findings. He developed a visual 
reasoning language for supporting complex strategic reasoning and decision making.  He 
served as scientific adviser to several governments, international institutions and large 
companies. Mr Von Müller is an external member of two multi-disciplinary research centers at 
the University of Munich, the Human Science Center and the Munich Center for 
Neuroscience, he is member of the Board of Trustees of the Max Planck Institutes of 
Neurobiology and Biochemistry, and he is co-editor of the Springer book series “On 
Thinking”. 
Abstract Constellatory diagnostics 
Constellatory diagnostics (CD) is a novel approach to support complex medical thinking and 
decision making. Its main task is to make sure that the best available knowledge is 
effortlessly available in all diagnostic situations. The MD just needs to represent the 
constellation of symptoms with a few finger strokes on a tablet. The methodological core of 
CD is that it doesn’t just aggregate individual symptoms but allows interpreting them in their 
specific constellation. By this, CD supports MDs in the way outstanding experts in this field do 
think. In basic research on advanced human cognition a fundamental complementarity 
between two basic modes of thinking has been found. One is the well-known, Boolean-type of 
rational concatenation of mental content. The other is the constellatory unfolding of meaning. 
Usually circumscribed by notions like “intuition”, “gut feeling” or “expert judgment”, it is far 
from “irrational”, it just follows a very different type of logic. The three basic principles of the 
logic of constellations are: (1) the mutual semantic unfolding of the involved components, (2) 
the emergence of an overarching meaning, and (3) the re-interpretation of the initial 
components in the light of the emergent overarching meaning. In evolutionary terms, 
constellatory logic might to be an exaptation of Gestalt perception, re-utilized in the domain of 
advanced conceptual thinking. Cognitive breakthroughs, from science to diagnostics, are 
characterized by an effortless interplay between the two basic modes of thinking. CD is the 
first practical application supporting both modes of thinking, and their effortless interplay. In 
parallel, CD makes sure that all residual risks and rare eventualities are taken into account. 
An optional by-product is a documentation that (a) minimizes the administrative burden of 
MDs, that (b) provides a high resolution record, e.g. for purposes of a patient transfer, and 
that (c) can prove comprehensive lege artis procedures. 
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 Prof. Maria Laura Bolognesi 
Position Associate Professor 
Organisation University of Bologna 
Department Department of Pharmaceutical Sciences 
Town Bologna 
Country Italy 
E-mail marialaura.bolognesi@unibo.it 
Abstract Styrylquinolines as amyloid chemical probes and theranostics in Alzheimer’s 
and prion diseases 
Alzheimer’s and prion diseases etiological mechanisms have been linked to a conformational 
change of normally expressed proteins that leads to the aggregation and abnormal deposition 
of protease-resistant and insoluble isoforms, namely amyloid-beta (Aβ) and prion protein 
scrapie (PrPSc). As the fibrillar aggregates of both these proteins are toxic to neurons, it has 
long been hypothesized that fibrils cause the underlying neurodegeneration. Thus, the 
amyloid plaques have been historically considered the neuropathological hallmark of these 
diseases determined at autopsy and, more recently, the classical biomarker for diagnostic 
purposes. In a personalized medicine perspective, a molecular biomarker can be utilized in 
the diagnosis, but also in staging and monitoring of therapy. On these basis, we explored the 
possibility of devising imaging probes to image the amyloid deposition in vivo and potentially 
provide treatment strategies against both maladies. To this aim, we focused on styryl 
derivatives, because several styryl compounds have been employed to detect Aβ plaques 
and have been successfully tested against PrPSc. Since the quinoline fragment is contained 
in many anti-prion compounds, we proposed to generate a library of styrylquinoline 
derivatives, to detect, and potentially inhibit fibrillar aggregates. The synthesis of the designed 
derivatives was achieved via a vinylogous variation of the Povarov reaction. They exhibited a 
promising activity against prion replication in ScGT1 cells and, importantly, showed no 
appreciable cytotoxicity. We also studied their activity as inhibitors of Aβ and PrPSc 
aggregation in vitro. To corroborate the possibility of employing them in vivo, we tested their 
ability to cross the BBB and investigated their native fluorescence in a variety of polar and 
non-polar environments to model their interaction with proteins, and provide the information 
required for their possible use as theranostic agents. 
 
 Prof. Darko Bosnakovski 
Position Assistant Professor 
Organisation University "Goce Delcev" Stip 
Department Faculty of Medical Sciences 
Town Stip 
Country F.Y.Republic Of Macedonia 
E-mail darko.bosnakovski@ugd.edu.mk 
Abstract Gene corrected FSHD-IPS cells, once step closer to cell therapy for 
Facioscapulohumeral muscular dystrophy 
Human induced pluripotent stem (IPS) cells overcome several disadvantages of human 
embryonic stem cells, including host specificity and ethical issues. These cells can be 
generating from different cell types of each donor making them suitable tool for autologous 
cell therapy and tissue engineering. Furthermore, iPS cells generated from patients with 
genetical disorders capture the disease genotype in the cell. These cells are good model for 
studying pathology of the diseases and testing different therapies. One approach is cell 
therapy by using specific cell types from genetically corrected  IPS cells 
Facioscapulohumeral muscular dystrophy (FSHD), one of the most common inherited 
myopathies, is caused by a contraction within a subtelomeric array of D4Z4 repeats 4q35.2. It 
is characterized by uneven and progressive weakness and atrophy of facial, shoulder and 
upper arm muscle.    
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To develop cell based study model for FSHD and relevant source for cell therapy we 
generated IPS cells from FSHD myoblasts and myoblasts from healthy donors. To induce 
myogenic differentiation FSHD-IPS cells were transduced with Myf5, one of the key myogenic 
transcriptional factors. Under certain conditions Myf5 modified cells differentiated in 
myoblasts and fused to form myotubes. DUX4 expression was detected in all stages of IPS 
myogenic differentiation, pluripotent, mesenchymal and myogenic stage. By this, we 
established relevant diseases model to study FSHD. However, to overcome the issues of 
comparison of IPS clones from different donors and variations acquired prior reprogramming, 
and in same time to generate adequate cells for tissue engendering, we genetically corrected 
FSHD-IP cells by removing 4qA161 allele. We targeted FSHD-iPS cells with a linear targeting 
vector bearing a single homology arm of 500 bp followed by the neo cassette and human 
artificial telomeric repeats (T2AG3), using zinc finger nucleases. Expression analyses reveled 
that corrected FSHD-IPS clones do not express DUX4. 
 
 Prof. Andrea Danani 
Position Professor 
Organisation University of Applied Sciences of Southern Switzerland 
Department Department of Innovative Technologies 
Town Manno 
Country Switzerland 
E-mail andrea.danani@supsi.ch 
Abstract System Information Therapy and Personalized Medicine 
Living organisms can nowadays be viewed as dynamic processes sustained by a ceaseless 
flows of matter, energy and information within so-called morphogenetic fields. Life is a far 
from equilibrium process and the process aimed to keep stability through dynamic changes 
has been recently defined as allostasis. Allostatic load is referred to the total amount of stress 
the whole system has to cope to maintain allostasis and leads to a decrease of health 
potential toward pathogenesis. Allostasis and allostatic load are in a dynamic relationship as 
an expression of the flow of informations due to adaptive dynamics and health and disease 
can be viewed as an expression of this dynamics. Information flows in biological system can 
be studied either by a chemical and molecular description either by an electromagnetic 
signals emission. It has been established, in the last decays, that electromagnetic signals are 
endogenously generated at different level in many cell components and supposed to play an 
active role in synchronizing either inner cell function at microscopic level either systemic 
adaptive response of organs, apparatus and whole organism. In this framework all the 
adaptive response both at microscopic and macroscopic level, either local or holistic, could 
be identified by their specific electromagnetic signals emission. Each specific adaptive 
reaction, being unique for any person at any time, will have his own specific and personal 
electromagnetic signature. System Information Therapy (SIT) is a developing clinical 
methodology employing medical devices working by a combination of endogenous and 
external electromagnetic signals with the aim of restoring the self regulation and self 
regeneration capability of the human being. This process has been clarified at the 
microscopic level with evidence of repatterning of cell membrane components or at 
epigenetic level with evidence of selective mRNA expression induction. At macroscopic level 
the self regulation effect has been, for instance, demonstrated in postural repatterning with 
evidence of disappearance of fluctuating asymmetry or in pain management . SIT is a new 
effective and efficient tool in personalized medicine allowing to cure each person by his own 
specific dysfunctional or pathological electromagnetic signals at local or systemic level. 
Moreover SIT is also a suitable tool in preventive medicine allowing to manage allostatic load 
in order to keep allostasis and coping efficiently with everyday stress of life. 
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 Mr Christos Kannas 
Position Researcher (Special Scientist) & PhD Student 
Organisation University of Cyprus 
Department Computer Science 
Town Aglantzia, Nicosia 
Country Cyprus 
E-mail chriskannas@gmail.com 
Abstract Towards a modular Web-based Workflow environment for enabling large scale 
Virtual Screening in Cancer Chemoprevention Research 
The vision of the GRANATUM  project is to bridge the information, knowledge and 
collaboration gap among biomedical researchers in Europe and beyond, ensuring that the 
biomedical scientific community has homogenized access to the globally available 
information and data resources needed to perform complex cancer chemoprevention 
experiments and conduct studies on large scale datasets. This way, GRANATUM will 
facilitate the social sharing and collective analysis of biomedical experts’ knowledge and 
experience, as well as the joint conceptualization and design of scalable chemoprevention 
models and simulators, towards the enablement of collaborative biomedical research 
activities beyond geographical barriers, helping researchers in this highly multidisciplinary 
field to manage the complex tasks involved in carrying out collaborative research. 
Within the scope of the GRANATUM project we have the task to implement a Web-based 
Virtual Screening Tool. It will provide the researchers with a set of In-Silico Tools and Models 
that will be used to create Virtual Screening Workflows aimed for the use in Cancer 
Chemoprevention Research. The Virtual Screening Tool will facilitate the use of In-Silico 
Tools from the Drug Discovery process and custom made Predictive Models based on the 
research on Cancer Chemoprevention. The researchers will be able to create Virtual 
Screening Workflows and Predictive Models. The GRANATUM platform will provide its users 
the functionality to share the Workflows and Predictive Models created, among them. The 
GRANATUM platform will facilitate mechanisms to retrieve information from various 
recourses in the Cloud and semantically interlink them to create a knowledge base for Cancer 
Chemoprevention. The results from the Virtual Screening Workflows will be used to update 
this knowledge base. 
As a proof of concept initially we will provide In-Silico Tools and Models to support research 
for cancer chemopreventive agents based on the human proteins ER-Alpha, ER-Beta and 
DNMT. 
 
 Prof. Saulius Klimasauskas 
Position Head of Department 
Organisation Insitute of Biotechnology, Vilnius University 
Department Department of Biological DNA Modification 
Town Vilnius 
Country Lithuania 
E-mail klimasau@ibt.lt 
Abstract Chemo-enzymatic approaches to genome-wide profiling of cytosine 
modifications 
Enzymatic methylation of cytosine at the 5 position in DNA serves as a key epigenetic 
regulatory mechanism in higher eukaryotes including humans. Aberrant DNA methylation 
correlates with a number of pediatric syndromes and cancer, or predisposes individuals to 
various other diseases. This reaction is carried out by methyltransferase enzymes (MTases) 
which catalyze the transfer of a methyl group from the ubiquitous cofactor S-adenosyl-L-
methionine (AdoMet). Recently, the sixth component of vertebrate DNA, 5-
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hydroxymethylcytosine (hmC), has been identified in genomic DNA from the brain and 
neuronal cells [1], which is likely involved in yet unknown epigenetic mechanisms. However, 
most existing methods used to query the modification status of CG sites in DNA are not 
suitable for analysis of hmC, which hampers studies of these new phenomena. To this end, 
we redesigned the methyltransferase reaction for covalent attachment of larger chemical 
moieties to DNA by rational engineering of the catalytic center and employing synthetic 
AdoMet analogs with extended propargylic sidechains [2], and employed atypical reactions of 
the cytosine-5 MTases with non-cofactor-like compounds that permit exchange and labeling 
of 5-hydroxymethyl groups in DNA [3,4]. Based on these chemo-enzymatic reactions we 
developed analytical tools permitting covalent derivatization, biotin labeling and affinity 
capture of DNA fractions containing different modified cytosines (hydroxymethylated and 
unmethylated CpG sites) and have adapted them for genome-wide mapping of the cytosine 
modifications using DNA microarrays. 
References: 
[1] S. Kriaučionis, N. Heintz. Science, 324, 929–930 (2009). 
[2] G. Lukinavičius et al.,  J. Amer. Chem. Soc., 129, 2758–2759 (2007).  
[3] Z. Liutkevičiūtė et al., Nat. Chem. Biol., 5, 400–402 (2009). 
[4] Z. Liutkevičiūtė et al., Angew. Chem. Int . Ed., 50, 2090–2093 (2011). 
 
 Prof. Yannis Missirlis 
Position Professor 
Organisation University of Patras 
Department Mechanical Engineering Department 
Town Patras 
Country Greece 
E-mail misirlis@mech.upatras.gr 
Abstract All the appropriate signals are necessary for engineering proper tissues 
The highly interdisciplinary area of tissue engineering, by its nature, involves several fields of 
research from basic materials development to stem cell handling to clinical applications. 
While the need for quick applications is driven by necessity we are still far away from 
understanding how the hybrid system of material scaffolds-cells-biomolecules operates 
optimally either in-vitro (in a bioreactor) or in-vivo. 
In our effort to monitor some basic responses of particular cells to specific environments we 
have developed a bioreactor able to supply a multitude of mechanical cues, singly or in 
combination to endothelial cells. 
In this presentation we will provide evidence of the importance of substrate stretching and 
frequency of stretching, of the shear rate of the flowing feeding medium on top of the cells, 
and of a simulated microgravity environment, especially by combining all these signals to the 
morphological adaptation of the cells and the rearrangement of its cytoskeletal proteins for 
each particular adaptation. 
 
 Dr Andreani Odysseos 
Position Director of Biomedical Research 
Organisation EPOS-Iasis, R&D 
Department Biomedical Research 
Town Nicosia 
Country Cyprus 
E-mail andreani@epos-iasis.com 
Abstract γ-Tocotrienol, a nutrient-derived natural product, induces differential 
modulation of the therapeutic efficacy of anti-EGFR Tyrosine Kinase Inhibitors  
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The Tyrosine-Kinase Receptor (TRK) family of proto-oncogenes, epitomized by the 
Epidermal Growth Factor Receptor (EGFR), provide a well-established system of cancer 
biomarkers. Mutations within parallel or cross-sectioning signaling pathways confer 
resistance to anti-EGFR therapies.  Dissecting molecular cascades and inter-molecular 
interactions in these pathways is therefore essential to overcome resistance and optimize 
anti-EGFR therapeutic interventions. γ-Tocotrienol is a minimally toxic poly(oxo)phenolic 
derivative of the vitamin E family with potent signal-modulating properties in colon and 
prostate cancer carcinogenesis.  
Herein we provide strong evidence that γ-Tocotrienol differentially modulates the efficacy of 
EGFR Tyrosine Kinase Inhibitors (TKI) in colon cancer models with diverse EGFR expression 
levels and discloses intermediate molecular markers of response interacting within the EGFR 
cascade. γ-Tocotrienol-modulated protein phosphorylation showed significant overlap with 
TKI -modulated protein phosphorylation. Combined with TKI in TKI-non-responding cells, γ-
Tocotrienol elicited novel hits representing kinases associated with the EGFR cascade for the 
first time and representing potential new intracellular targets. These findings are further 
supported by our temporal pharmacoprotemics studies where γ-Tocotrienol exhibited strong 
caspase-independent pro-apoptotic activity in EGFR overexpressing cell lines, cross-
sectioning the EGFR axis and maintaining a dynamic interplay between tyrosine 
phosphorylation and nitrosylation, underlying these signaling events. 
In order to further reveal the molecular basis of synergistic or antagonistic outcome of 
combinatorial signals elicited by combinations of biopharmaceuticals, 
Bioluminescence/Fluorescence Resonance Energy Transfer (BRET/FRET) systems,  
constituting powerful tools in the assessment of efficacy of candidate molecular leads have 
been developed. Application of BRET/FRET assays has enabled the monitoring of inter-
molecular interactions between established and newly identified target proteins, in live- cell 
settings. FRET signals induced by fluorescently labeled γ-Tocotrienol suggested that EGFR 
may also serve as a candidate target of this agent.  
Conclusively, these findings provide substantial evidence for the potential role of γ-
Tocotrienol, a minimally toxic natural agent, in enhancing sensitivity and overcoming 
resistance to anti-EGFR therapies and are, therefore, expected to further enable patient 
stratification for combined therapies in the clinical setting. 
 
 Prof. Harald Schmidt 
Position Professor of Personalised Medicine & Pharmacology 
Organisation Maastricht University 
Department Pharmacology 
Town Maastricht 
Country Netherlands 
E-mail h.schmidt@maastrichtuniversity.nl 
Abstract Personalised cardiovascular medicine: From antioxidants to validated 
molecular sources and targets of oxidative stress 
Rationale 
Oxidative stress has been postulated for many years as a major cause and driver of vascular 
disease states such as coronary artery disease, peripheral artery disease, and stroke. 
However, all therapeutic applications have focused on antioxidants with little or no success 
and no clinical implications. Here we show that identifying and specifically targeting the 
molecular sources of vascular oxidative stress and its target proteins is much more promising 
and provides specific, biomarker-assisted therapeutic avenues.  One of the major functional 
targets of oxidative stress is the nitric oxide-cyclic GMP signalling pathway (NO-cGMP). 
Relevant sources include the innate immune response enzyme, gp91phox, a NADPH 
oxidase, now termed NOX2. Related NOX2-like enzymes are expressed on many surface 
cells (endothelium, epithelium) as an extended innate immune or stress response system.  
Methods & Results 
NOX deficient mice were subjected to ischemia, ischemia-reperfusion and metabolic stress 
models. NOX1 promotes atherosclerosis and is associated with an hypertensive phenotype. 
NOX4 is upregulated in ischemia-reperfusion and causes neurodegeneration after stroke. 
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Impaired NO-cGMP signalling is found in heart failure and coronary artery disease and can 
be targeted in stroke, hypertension and diabetes. eNOS recoupling appears to be efficient in 
peripheral artery disease. Biomarkers indicate both oxidative stress as well dysfunctional NO-
cGMP signalling. 
Conclusion 
These data suggest that oxidative stress can be efficiently targeted using inhibitors of NOX or 
activators/stimulators of cGMP formation. 
Clinical Relevance 
Together with recent genetic evidence, the NO-cGMP pathway in conjunction with NOX-
derived oxidative stress appears to be the first mechanism-based cardiovascular therapy. 
 
 Prof. Alain van Gool 
Position Coordinator Personalized Medicine 
Organisation Netherlands Organization for Applied Scientific Research (TNO) 
Department Metabolic Health Research 
Town Leiden 
Country Netherlands 
E-mail alain.vangool@tno.nl 
Abstract Towards Personalized Medicine in Metabolic Disease 
The field of oncology has paved the way in the use of biomarkers in translational and 
personalized medicine, enabling the selection of most responsive patients for specific 
treatments. Most successful examples are those where disease can be linked to a single 
genetic driver and drugs are used to shut down an overactivated pathway. A challenge 
appears however when these lessons-learned are to be applied to complex chronic diseases 
as metabolic syndrome. The progression from a healthy state to obesity,  diabetes and 
ultimately to diabetes complications, including cardiovascular events, nephropathy and brain 
disorders to name a few, is based on a gradual disturbance of multiple equilibria. Influencing 
one equilibrium using specific nutrition or drugs affects other pathways in this complex 
system, resulting in seemingly positive effects on short-term but deleterious effects in 
seemingly non-related diseases on long-term. Key to successful treatment in metabolic 
disease is the use of system biology, not only to elucidate key disease mechanisms  and 
identify key biomarkers, but also to use panels of such biomarkers to monitor the effect of 
interventions on the human system as a whole, and timely adjust when needed. Opportunities 
to implement such approach in health care through public private partnerships will be 
discussed. 
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 Mr Aristos Aristodimou 
Position Researcher 
Organisation University of Cyprus 
Department Department of Computer Science, Pure and Applied Sciences (FST-01) 
Town Nicosia 
Country Cyprus 
E-mail aris.aristodimou@gmail.com 
Abstract Linked2Safety - A next generation, secure linked data medical information 
space for semantically-interconnecting electronic health records and clinical 
trials systems advancing patients safety in clinical research 
Linked2Safety is an FP7 project funded by the European Commission under the area of ICT 
for health. The vision of the project is to advance clinical practice and accelerate medical 
research, by providing pharmaceutical companies, healthcare professionals and patients with 
an innovative semantic interoperability framework facilitating the efficient and homogenized 
access to distributed Electronic Health Records (EHRs). Even though EHRs contain an 
increasing wealth of medical information, the European healthcare information space is 
fragmented due to the lack of legal and technical standards, cost effective platforms, and 
sustainable business models. The Linked2Safety project aims to build the next-generation, 
semantically-interlinked, secure medical and clinical information space in the enlarged 
Europe. This will allow dynamically discovering, fruitfully combining and easily accessing 
medical resources and information contained in spatially distributed EHRs. Moreover it will 
leverage the reuse of EHRs in clinical research, towards the early detection of potential 
patient safety issues, based on the genetic data analysis and the extraction of the bio-
markers associated with an identified type of an adverse event. It also aims to support sound 
decision making, towards the effective organization and execution of clinical trials, allowing 
health carers and medical scientists to easily submit their own query and get homogenized 
access to high-quality medical data. 
Linked2Safety will allow the analysis of all the available data of the subjects, such as genetic, 
environmental and their medical history during a clinical trial, leading to the identification of 
the phenotype and genotype factors that are associated with specific adverse events and 
thus early detection of potential patients’ safety issues. It will also enable subject selection for 
clinical trials through the seamless and standardized linking with heterogeneous EHR 
repositories, providing advice on the best design of clinical studies. Finally it aims to develop 
proof-of-concept pilot clinical trials design studies to validate and evaluate the Linked2Safety 
results. The University of Cyprus is responsible for the creation of the Linked2Safety Data 
Analysis Space. This includes the design and development of data mining techniques on 
genotypic and phenotypic data for single hypothesis testing and the identification of bio-
markers associated to adverse events. All of the knowledge created by this system will be 
extracted, so that it can be used for future data sets and for an adverse events early detection 
mechanism. 
 
 Dr Jaime Castillo-León 
Position Assistant Professor 
Organisation Technical University of Denmark 
Department Micro and Nanotechnology 
Town Lyngby 
Country Denmark 
E-mail jaic@nanotech.dtu.dk 
Abstract Self-assembled Peptide and Protein Nanostructures in Diagnosisrelevance 
Biological compounds able to organize into nanostructures such as self-assembled peptides, 
proteins or amphiphile compounds play an active role in the development of electrochemical 
sensors and electronic sensing devices (Field effect transistors, FETs) used for the detection 
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of compounds of biomedical importance. 
Structures such as nanopores, nanowires or nanotubes can be synthesized using proteins, 
self-assembling aromatic peptides or viruses as building blocks. These nanostructures can be 
utilized as sensors to get information regarding the concentration, structure and dynamics of 
a single molecule that is translocated inside a channel protein as in a protein nanopore-based 
sensor.  
Using manipulation techniques such as dielectrophoresis, self-assembling peptide nanotubes 
can be immobilized on top of metal microelectrodes in order to characterize their electrical 
properties. These non-conductive nanostructures can then be modified on its surface using 
antibodies or enzymes to fabricate very sensitive devices such as FETs for the detection of 
compounds of biomedical relevance (viruses, glucose, metals, neurotransmitters, etc) 
through impedance changes. 
Electrochemical biosensors can be developed by immobilizing these biological 
nanostructures by physical adsorption or by trapping those using polymers on the surface of 
metal transducers. In this case the concentration of compounds is monitored through 
changes in the current which is proportional to the changes in analyte concentration. In this 
situation the nanostructures increase the surface area of the metal transducer.  
In this work the different building blocks used for the synthesis of these biological structures 
will be discussed as well as their electrical and structural properties that make them suitable 
for the development of sensing devices. Additionally, the techniques for their controlled 
immobilization and functionalization will be presented.  
Finally a review of the different sensing devices will be listed discussing its advantages and 
challenges when compared with sensing devices developed using nanomaterials traditionally 
used such as carbon nanotubes or silicon nanowires. 
 
 Dr Inga Dadeshidze 
Position Deputy Director, Senior Scientist 
Organisation Institute of Pharmacochemistry 
Department Administraton, Pharmaceutical Technology 
Town Tbilisi 
Country Georgia 
E-mail idadeshidze@yahoo.com 
Abstract Antioxidant natural compounds transermal delivery and hypoglicamic effect - 
personalized approach 
Personalized approach is extremely important for the treatment of diabetes mellitus. Non-
enzymatic, free radical-mediated oxidation of biological molecules, membranes and tissues is 
present in a variety of pathological events, including diabetes mellitus. Hyperglycaemia 
appears to play a major role in free radical production .  
The skin, as the outermost barrier of the body, comes in direct contact with many  
environmental factors. Substances with antioxidant properties could inhibit or significantly 
delay the above mentioned phenomena. Topical application of antioxidants may result in a 
sustained antioxidant capacity of the skin, possibly due to antioxidant synergisms. Another 
advantage of the skin is that it can be used to possibly deliver the antioxidant agent for 
obtaining systematic effects. 
The isolation of polyphenols from plants grown in Georgia and their phytochemical 
investigation have been done by the Laboratory of Polyphenols of Institute of 
Pharmacochemistry. The high antioxidant activity of polyphenols: Robinin, Astragalegoside, 
Isoastragalegoside, Kaemferol; Rutin, Anthocyanes, Sums: Geranium pussilum and 
Geranium robertianum, has been determined by different  methods. Their anti-inflammatory 
and antidiabetic activities by topical application have been examined on albino hairless mice 
SKH-1. The studes have been done in collaboration with Schools of Pharmacy and Medicine 
of  the University of Athens. The in vitro release of active natural compounds from 
formulations was examined with the membrane diffusion method. 
The studies have been done considering pharmacogenetic and pharmacogenomic factors. 
Antidiabetic activity by topical application has been studied on mice. Insulin has been 
measured at the end of experiment in plasma samples by using DRG ultrasensitive mouse 
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ELISA Insulin enzymeimmunoassay. According the results of clinical studies developed 
semisolid formulation and due to antidiabetic activity of the selected compound by topical 
application we consider the further studies of this natural product as a personalized medicine 
against diabetis and its complications.  
 
 Dr Simeone Dal Monego 
Position Application Specialist 
Organisation CBM Scrl 
Department Optical Imaging Laboratory 
Town Trieste 
Country Italy 
E-mail stefania.biffi@cbm.fvg.it 
Abstract Combined high resolution and functional CT imaging in an asthma mouse 
model, utilizing synchrotron radiation  
S. dal Monego1*, C. Dullin2*, S. Mohammadi3,4*, E. Larsson3,5, C. Garrovo1, A. Lorenzon1, G. Tromba3, S. Biffi1 
* Authors contribute equally to the work 
(1) C.B.M. Cluster in Biomedicine, C.B.M., Trieste (Italy) 
(2) Diagnostic Radiology, University Medical Center Göttingen (Germany) 
(3) Elettra Synchrotron, SYRMEP, Trieste (Italy) 
(4) Department of Physics, University of Trieste, Trieste, (Italy) 
(5) Department of Industrial Engineering and Information Technology, University of Trieste, Trieste, (Italy) 
 
Background: Asthma is a common growing disease affecting over 300 million people 
worldwide. Therefore, development of novel therapies are of great demand which will be 
normally evaluated in preclinical asthma mouse models. Asthma is characterized by 
inflammation and air hyper responsiveness accompanied with airway wall thickening. To 
assess these alterations in the lungs of such mouse models, imaging methods with superior 
spatial resolution need to be applied. These methods are by definition limited in terms of 
sensitivity which hampers the detection of inflammation at the same time. 
Method & Findings: We developed a novel approach to expand the high resolution microCT 
imaging technique with a functional aspect by utilizing barium labeled macrophages. 
Immortalized alveolar macrophages were kept in culture, labeled with clinical used barium 
containing contrast agent for 24h intra tracheal administered (6 Mio cells each) in asthma as 
well as in control mice. Mice were sacrificed 24h later and analyzed with phase contrast 
microCT at the SYRMEP beamline of the Elettra synchrotron (Trieste, Italy). A single distance 
phase retrieval algorithm was applied to retrieve phase information of the scanned lung 
regions. The reconstructed data showed the effectiveness of the technique to differentiate 
barium from lung tissue. Compared to control and blank samples, in asthmatic mice not only 
a higher barium content has been found, also increased soft tissue volume, reduced air 
volume and shrunken air pathways are demonstrated. 
Discussion: Phase contrast enables delineation of the airways in great detail and allows 
therefore the analysis of weak alterations in their pathology. Decoupling phase and 
absorption effects mixed in the acquired data was achieved by utilizing a novel phase 
retrieval algorithm, enabling bio-distribution analysis of the macrophages. A great difference 
between the concentrations of labeled macrophages in the lungs of asthma animals 
compared to the controls was found. We therefore believe, that for the first time a functional 
as well as high resolution microCT imaging approach in an inflammatory lung disease model 
has been established with is of great potential for clinical applications in the near future at our 
opinion. 
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 Dr Sarah Denford 
Position Associate Research Fellow 
Organisation University of Exeter 
Department Health Services Research 
Town Exeter 
Country United Kingdom 
E-mail sarah.denford@pms.ac.uk 
Abstract Methods of individualising treatments for patients with chronic conditions 
Background  
For long term conditions, treatment regimes can be complex, time consuming, and have 
serious adverse effects. Patients have various concerns and priorities surrounding 
treatment(s). Healthcare providers use various methods to prescribe treatments based on 
individual factors; however, there is little guidance to support healthcare providers and 
patients to achieve individualised treatments.  
We aimed to:  
(i) Clarify what individualisation means in the context of chronic disease 
(ii) Explore the methods/techniques that are used to individualise treatments.  
Method  
A review of the literature was conducted. The Cochrane Central Register of Controlled Trials, 
EMBASE, CINAHL, MEDLINE, and PsychInfo were searched for papers published between 
1990 and 2011. To supplement the literature review a qualitative exploration of healthcare 
providers’ understanding of individualisation, and methods used to individualise treatments 
was conducted. Ten healthcare providers were interviewed. Data were analysed using 
thematic analysis.  
Results  
The interview study revealed that healthcare providers were often uncertain about what 
individualisation meant.   Definitions included: doing what the patient wants; doing what (the 
healthcare provider thought) was best for the patient; not following guidelines; trading off risks 
and benefits; and treating medical versus social problems. 
The literature review revealed a number of methods used by healthcare providers to 
individualise treatments. These methods were broadly categorised as methods used to: make 
initial diagnoses / treatment decisions; review patients’ treatments; involve the patient and 
incorporate patient preferences in treatment decisions; and support patients outside the 
consultation.    
Conclusions 
Further research is needed to refine the concept of individualisation; develop a 
comprehensive list of techniques used by healthcare providers to support patients in 
achieving individualised treatments; and develop a tool kit for supporting individualised 
treatments.   This could be practically useful in clinical practice in supporting patients and 
healthcare providers achieve individualised treatments, as well as advancing our 
understanding of individualisation. 
 
 Dr Liudmila Dolmatova 
Position Senior Researcher 
Organisation V.I. Il’ichev Pacific Oceanological Institute 
Department Department of Biochemical Technologies 
Town Vladivostok 
Country Russia 
E-mail dolmatova@poi.dvo.ru 
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Abstract Apoptosis-Modulating Action of the New Extract from Far-Eastern 
Holothurians 
Anticancer effects of most drugs are related to their apoptosis-inducing capacities. However, 
chemotherapy usually has numerous side-effects. Recently, some extracts from marine 
invertebrates, holothurian Cucumaria frondosa including, were suggested for treatment of 
several types of cancer. The extracts damaged cancer cells via apoptosis without manifest 
toxic side-effects.  The content of the main apoptosis-inducing substances, triterpenoid 
glycosides, in tissues of Far-Eastern holothurians Eupectacta fraudatrix  is significantly higher 
than that in C. frondosa. The object of the current work was research on apoptosis-
modulating effects of the extract from Far-Eastern holothurians and the studies on safe using 
of the extract. It was shown that at doses more than 1000-fold lower than LD50, the extract 
given once a day for three days decreased levels of both apoptosis and nitrotetrazolium blue 
at the reversed dose-dependent manner  in mice peritoneal macrophages. Additionally, it 
decreased activities of antioxidant enzymes catalase and glutathione reductase in direct 
dose-dependent manner. Obviously, the high antiradical activity of the extract induced 
“energy-conserving” conditions of the work of the antioxidant system in the normal cells. 
Nevertheless, the lowest of the doses studied significantly increased apoptosis in 
macrophages treated with stress-agent (bacteria) compared to the action of bacteria. On the 
contrary, the highest dose decreased the apoptosis in bacteria-treated cells. Research on the 
mechanisms of action of the extract on model system (phagocytes of holothurian E. 
fraudatrix) revealed that they were similar to those for dexamethasone. Apparently, the 
extract and dexamethasone competed in binding to cell surface receptors. One-year lasting 
supervision of mices after one-month treatment with the extract showed no changes in blood 
and liver biochemical and immunological markers. Taken together with data on possibilities of 
artificial cultivation of E. fraudatrix, the extract can be considered to be promising novel 
therapeutic agent for different types of cancer, sarcoma including.  
 
 Prof. Gunars Duburs 
Position Head of laboratory 
Organisation Latvian Institute of Organic Synthesis 
Department Membrane active compounds 
Town Riga 
Country Latvia 
E-mail gduburs@osi.lv 
Abstract Self-assembling synthetic lipids comprising privileged pharmaceutical 
structures 
"G.Duburs, A.Plotniece, B,Skrivele, K.Pajuste 
Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga LV 1006, Latvia 
We have designed and synthesised amphiphilic lipids possessing several activities important 
to medicine chemistry. 1,4-Dihydropyridine (1,4-DHP) derivatives possess, depending on 
substituents, several pharmacological activities, e.g., anti-hypertensive, anti-anginal, memory 
enhancing, neiroprotective, anti-Alzheimer, anti-diabetic, anti-cancer, anti-oxidant, anti-
mutagenic, growth stimulant and geroprotective [1,2].  
It is possible to obtain compounds possessing selective activity or multifunctional molecules 
for polypharmacology. Self-assembling lipid type 1,4-DHP derivatives form nanoaggregates 
and possess gene transfection properties [3] and antiradical activity as well. 
Unsubstituted in position 4 dialkyl-1,4-DHP-dicarboxylates are antioxidants and antiradical 
compounds. 4-Aryl-1,4-DHPs have low antiradical activity, but insertion of strong electron-
withdrawing substituents (pyridinium, substituted pyridinium) in 2- and 6-methyl groups of 1,4-
DHPs leads to active antiradical compounds. 
So, it is shown that self-assembling lipids, gene delivery agents, in case of insertion of 
privileged 1,4-DHP moiety obtain novel - antiradical activity.   
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Abstract Personalised E-health care for patients with chronic somatic diseases 
Chronic somatic conditions, such as rheumatoid arthritis, psoriasis, diabetes or multiple 
sclerosis, result in severe physical symptoms and psychological adjustment problems in 
about 30-40% of the patients. Previous research has shown that these physical and 
psychological adjustment problems can be effectively treated by personalised self-
management care approaches for patients at risk for long-term adjustment problems.  
The Internet has become a main medium for the delivery of computer-tailored self 
management interventions for patients with chronic somatic conditions. The greater flexibility, 
the fulltime accessibility, the potential high reach and the possible higher cost-effectiveness 
make the Internet an attractive channel for delivery self-management interventions.  
Based on effective face-to-face treatments, a personalized E-health application for tailored 
self-management for patients with chronic somatic conditions has been developed in close 
cooperation with patient organizations. After screening of patients' risk profiles, tailored 
treatment modules are chosen, focusing on individualized programs for coping with pain, itch, 
fatigue, negative mood, or social relationships. During the E-health program, patients have 
weekly mail contact with the therapist with daily home-work assignements that are indivdualy 
tailored to the specific problems.  
Results indicate that applying personalized E-health to risk groups of patients is feasible and 
patients perceive more advantages than disadvantages for E-health treatments in 
comparison with face-to-face treatments. Reviews on the effectiveness of the E-health self-
management treatments in patients further suggest beneficial effects for physical and 
psychological functioning comparable to face-to-face treatments.  
Tailored E-health self-management programs for patients with chronic somatic diseases 
seems to promising to offer personalized E-health care in an (cost)effective and userfriendly 
way. 
 
 Dr Nuno Garcia 
Position Researcher 
Organisation University of Beira Interior 
Department Instituto de Telecomunicacoes 
Town Covilhã 
Country Portugal 
E-mail ngarcia@di.ubi.pt 
Abstract Challenges and Opportunities in Ambient Assisted Living 
The creation of new devices and frameworks for provision of Ambient Assisted Living (AAL) 
promises to revolutionize the manner at which Health Systems have addressed health 
service for its citizens. 
Yet, despite the age of the telemedicine concept, the scope and degree of implementation of 
such platforms is far from ideal, thus failing to bring the much needed advantages. 
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In this short presentation, the challenges facing AAL will be addressed, from the point of view 
of its main stakeholders. New opportunities for AAL will also be discussed, primarily focusing 
on those resulting from the interaction of different areas, such as mass-media, computer 
science and telecommunications, and wearable medical devices. 
The main conclusions will be drawn, from different points of view, further contributing to a 
wide-picture of the current standpoint of AAL. 
 
 Iulian Ionita  
Position Lecturer Professor 
Organisation University of Bucharest 
Department Faculty of Physics, Dept. Optics-Spectroscopy-Plasma-Lasers 
Town Bucharest-Magurele 
Country Romania 
E-mail i_ionita@yahoo.com 
Abstract Monte Carlo simulation for personalized laser treatment of inflammatory 
process 
Underlying mechanisms of low power laser irradiation beneficial effects in treatment of 
chronic inflammatory conditions are yet far from being explained, as there are many aspects 
of photon propagation in anisotropic media. Aims of present studies were to disclose 
characteristics of laser light penetration in live tissues and to reveal processes involved in 
cellular effects of soft laser irradiation at power densities comparable to those achievable in in 
vivo irradiated living tissues. We measured the diffuse reflectance in the area of inflammation 
of laser treated patients and used Monte Carlo simulations in order to obtain characteristic 
parameters of absorption and scattering phenomena and to compute the absorbed radiation 
dose at cellular level. Thus we can project the personalized treatment total dose and 
irradiation regime calculated for target tissue following Monte Carlo simulations. 
 
 Dr Vitali Kalantaryan 
Position Associate Professor 
Organisation Yerevan State University 
Department Microwave Radiophysics 
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E-mail vkalantaryan@yandex.ru 
Abstract Millimeter Wave Induced Suppression of Sarcoma Growth in Mice 
Unlike now widely applied traditional methods treatment of tumors by means of ionizing 
radiation (gamma therapy, proton therapy) and the chemotherapy, the considered method of 
MM-therapy is non- ionizing and non- invasive and   hence is completely deprived of any 
harmful side effects. The present study was undertaken to investigate whether low-power 
(non-thermal) millimeter range electromagnetic radiation can act on tumor of mice in vivo 
without cytostatic agents. The present study has demonstrated the potential clinical 
application of low power coherent millimeter electromagnetic waves without damaging other 
tissues, without antitumoral drugs and harmful ionising radiotherapy. 
It is known that with the help of differential melting curves (DMC) it can be distinguished DNA 
tumor sarcoma from DNA isolated from the liver of healthy mice. DMC-2 of tumor DNA are 
shifted relatively DMC-1 of the DNA healthy animals to lower temperatures, and in the DMC 
of tumor DNA there are appeared the additional peaks in the 52-60ºC, which is absent for 
DMC of liver DNA of healthy animals. The effect of MM waves with a frequency of 42.2 GHz 
is investigated in vivo on the structure of DNA secondary structure of sarcoma 37.  
After 15 sessions of MM-therapy without cytostatic drugs, at animals of the irradiated 0,5hour 
was observed an inhibition of tumor growth by 33.5% compared with a control group and a 
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sharp suppression of DNA-methylation level 2.5 times as much. The DNA-2 has the high 
level of methylation (4,7 mol%), which after 0.5 hour influence of MM-radiation becomes (2.2 
mol%) close to the corresponding value for DNA-1 (1,9 mol%). The received results are 
correlated with the spectrophotometric data. Under the influence of MM-radiation the values 
of temperature  (Tm0C) and interval ( T0C) of melting  of DNA-2 are changed and approach 
to the corresponding values of DNA-1. 
 
 Dr Matej Kastelic 
Position Researcher 
Organisation Faculty of Medicine, Institute of Biochemistry 
Department Laboratory of  pharmacogenetics 
Town Ljubljana 
Country Slovenia 
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Abstract Genetic Polymorphisms Modifying Oxidative Stress and Response to Acute 
Antipsychotic Treatment 
It has been suggested that genetic polymorphisms modifying oxidative stress may influence 
the response to antipsychotic treatment. In the present study we investigated the influence of 
polymorphisms in the Catalase (CAT), Superoxide dismutase (MnSOD) and Cytochrome P 
450 17-hydroxylase (CYP17) genes on the response to acute antipsychotic treatment of 
schizophrenia in 74 patients acutely treated with haloperidol or risperidone. CAT C-262T, 
MnSOD Ala-9Val and T-C transition (A2 allele) in the 5' polymorphism in the promoter region 
of the CYP17 were genotyped by real time PCR assay and sequence specific PCR. 
Psychopathological symptoms were assessed with BPRS and CGI twice: 8-12 and 36-40 
days after the first dose of antipsychotic. Adverse events were assessed with the SAS, BARS 
and AIMS scales. The respective genotypes frequencies were: CAT C-262T: CC 0.384; CT 
0.507 and TT 0.110; MnSOD Ala-9Val: ValVal 0,338; ValAla 0,568; AlaAla 0,095 and CYP17: 
TT 0,243; TC 0,527 and CC 0,230. When controlled for age, gender, BMI, illness duration, 
number of previous hospitalizations, drug type and dosage patients with at least one CAT T 
allele (CT + TT genotype) had significantly higher total AIMS scores (P=0.022) and total 
BARS scores (P=0.010) than patients with two CC genotype. We did not observe any 
statistical significant association between CAT C-262T genotype and the efficacy of treatment 
although it did affect the baseline BPRS score (P=0.044). MnSOD Ala-9-Val and CYP17 (A2 
allele) gene polymorphisms did not significantly influence neither the EPS neither the efficacy 
of treatment. Our results support the impact of CAT C-262T polymorphism on the occurrence 
of side effects in acute antipsychotic treatment in Slovenian schizophrenia patients. 
 
 Prof. Jan Lehotsky 
Position Professor 
Organisation Comenius University 
Department Medical Biochemistry 
Town Martin 
Country Slovak Republic 
E-mail lehotsky@jfmed.uniba.sk 
Abstract Selected Gene Polymorphisms in Ischemic Stroke and Depressed Patients: 
Possibilites for Tailored Therapy 
The neurobiological basis of ischemic stroke and postischemic depression is not yet clarified. 
We have focused on several genes which could be connected with the pathogenesis of 
ischemic stroke and depression. Angiotensin converting enzyme (ACE), as a  part of the 
renin-angiotensin system, is  important factor in blood pressure regulation.  Incidence of D 
allele is associated with higher protein level and its activity.  Serotonin-transporter-linked 
promoter (HTTLPR) is a degenerate polymorphic region in the gene that codes the serotonin 
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transporter. Its polymorphism is connected with neuropsychiatric disorders. Likewise, S allele 
is associated with the functional reduction as compared to L allele.Glutathione-S-tranferases 
(GST) detoxify a broad range of xenobiotics and carcinogens. The most studied 
polymorphisms are in families of GSTM1, GSTT1 and GSTP1. In our study we tested the 
gene polymorphisms in three groups of patients, with: i) ischemic stroke ii) depression, and iii) 
healthy controls. In the DD polymorphism of ACE gene, the depressed pacients exhibit higher 
frequency of DD genotypes in comparison  to controls. Stroke patients exhibit only non-
significantly lower frequency in comparison to controls.  So far, we did not observe any 
significant differences in allelic frequency for HTTLPR gene neither for depressed nor 
ischemic groups in comparison to controls. Our results suggest that ACE DD genotype is 
increased in depressed pacients. Analysis of selected polymorphisms of GSTM1 and GSTT1 
genes show higher frequency of GSTM1 null and GSTT1 wild  genotypes. 
 
 Prof. Federico Licastro 
Position Professor of Immunology 
Organisation University of Bologna 
Department Experimental Pathology 
Town Bologna 
Country Italy 
E-mail federico.licastro@unibo.it 
Abstract Pro inflammatory genetic risk profile in periodontal disease 
Background:  Periodontal disease caused by dental plaque is characterized by the clinical 
signs of infection, chronic inflammation and loss of periodontal tissue support. Bacteria and 
other pathogens colonize tooth surface and gingival sulcus, trigger chronic inflammatory 
responses with the release of cytokine and other inflammatory mediators which contribute to 
the loss of  the connective tissue and the supporting bone of the teeth. Periodontitis is a multi-
factorial disease and several risk-factors are involved in its pathogenesis. In fact, with 
infections other environmental, metabolic and genetic factors able to interfere with host 
immune responses may increase the propensity to develop the disease.  Here, pro-
inflammatory genetic background  in patients with periodontal diseases was investigated to 
identify genetic risk factors associated with the disease. 
Methods: Single nucleotide polymorphism (SNP) of Vascular Endothelial Growth Factor 
(VEGF), Alpha-1-Antichymotripsin (ACT), Idrossi-Methyl-Glutaril-CoA-Reduttase (HMG-CR), 
Interferon Gamma (INF-γ), Interleukin-1 Beta (IL-1ß), Interleukin 10 (IL-10), Interleukin 6 (IL-
6)  and Tumor Necrosis Factor Alpha (TNF-α) genes in patients and controls were 
investigated.  SNPs were assessed by a PCR or by Real Time-PCR methods. 
Results:  The C allele of VEGF, the A allele of IL-10 and the GG genotype of TNF-α were 
more frequent in patients with periodontal diseases than in controls. The concomitant 
presence of the three genetic factors strongly increased the risk of periodontitis. 
Conclusion: Our data  support the notion that impaired regulation of inflammatory responses 
plays a role in the history of periodontal disease and VEGF, IL-10 and TNF-α genes show a 
synergistic role in the disease.  Genetic risk factors may be used to set up a genetic risk 
profile and implement the screening of unaffected subjects with an increased individual 
susceptibility of developing periodontitis.  
 
 Dr Eriketi Loizidou 
Position Research Scientist 
Organisation University of Cyprus 
Department Biological Sciences 
Country Cyprus 
E-mail eloizido@ucy.ac.cy 
Abstract Rational design of Argyrin-based analogues as selective inhibitors of the 
51 
 
proteasome 
Proteasomes recognize and digest protein substrates that have been marked for degradation 
by the attachment of an ubiquitin moiety. Owing to their broad involvement in many cellular 
processes, proteasomes play a key role in many diseases, such as cancer. Therefore, 
proteasomes have been regarded as an attractive but complicated target for drug design.   In 
eukaryotes, association of the 20S proteasome with the 19S regulatory ‘cap’ complex yields 
the 26S proteasome. The proteolytic core, active sites β1, β2 and β5 that exert caspase-like, 
trypsin-like and chymotrypsin-like activity, respectively, resides within the 20S subunit.  
Inhibitors of the proteasome have to be highly specific, because proteasomes are very 
abundant in eukaryotic cells. The therapeutic index of proteasome inhibitors that specifically 
inhibit only one or two of the eukaryotic proteasome’s active sites is expected to be larger 
than of broad proteasome inhibitors. Natural products have shown an excellent track record 
as medicinal agents and continuously find clinical applications despite the large number of 
synthetic drugs.  
Herein, we report the results of our effort to design new inhibitors, inspired by nature, that 
selectively inhibit each of the proteasome activities, independently. We selected Argyrin A, a 
cyclic peptide isolated from the myxobacterium Archangium gephyra, and potent proteasome 
inhibitor, as our starting point upon which new compounds will be built. We performed an in-
depth analysis of the binding conformation, binding site interactions and energetics of binding 
using DFT optimized molecular-docking simulations of Argyrin A to the three active sites 
utilizing a "humanized" 20S proteasome model. We describe the spatial orientation of Argyrin 
A in each active site, and identify the determinants of selectivity and binding activity. Through 
this we provide our rational for the design of new argyrin-based analogues, each ranked 
independently by several docking algorithms to identify potent and most importantly selective 
proteasome inhibitors.  
 
 Dr Florence McCarthy 
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Abstract (Iso)Ellipticines and derivatives as selective CNS cancer therapeutics 
The natural product ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole) exhibits potent anti-
cancer activity and has been subject to much study since its isolation in 1959.(1) Its 
mechanism of action is multimodal, including DNA intercalation, topoisomerase II inhibition 
and inhibition of several kinases.(2-5)  
Although synthetic routes to ellipticines and their biological activity have been well 
documented, a simple synthetic analogue of ellipticine, namely isoellipticine, has not been 
extensively investigated. Given their structural similarity and likely bioactivity, we have 
embarked on a programme of drug discovery centered on the isoellipticine template. 
We hereby report the synthesis of a panel of novel ellipticine and isoellipticine derivatives, 
including 7 & 11 substituted isoellipticines and isoellipticinium salts.(6) Biological evaluation of 
selected compounds has led to the discovery of excellent potency for growth inhibition of 
numberous cancer cell lines and in particular for one subgroup, selectivity against the growth 
of CNS cancers.  
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Abstract Optically Activatable “Mitocans” as Molecular Probes for Colon Cancer 
Specific Targets 
Optical imaging is an important tool in the life sciences for the detection of gene expression 
and protein-ligand interactions. Although many of the techniques are restricted to in-vitro 
applications, due to problems with optical access or labeling, optical imaging is being 
increasingly used for in-vivo imaging as well. Absorption, reflectance, fluorescence, or 
bioluminescence can be used as the source of contrast. Endoscopic, fiber optic based, 
instrumentation is being developed to allow non-invasive imaging of internal organs. Usually, 
optical contrast agents have to be used to obtain high specificity and sensitivity. Highly 
specific probes are available that can label a single molecular species (e.g. GFP-fusion 
proteins). Metabolic processes can be investigated with probes that are activated by 
molecular interactions (e.g. BRET/FRET) or enzymatic reactions. Optical techniques can 
even map the activity of genes. In the context of the widely approved new roadmap to drug 
development, molecular imaging application for both identification and validation of response 
biomarkers defines one of the major pillars in the process.  
Here in we present a new approach to introduce potent optically active pro-apoptotic 
derivatives of nutrient-derived lipid-soluble isoprenoids, as target-specific anti-cancer agents. 
Cell trafficking studies disclosed potent mitochondriotropic effect. Enzymatic hydrolysis of 
these “mitocans” results in alteration of optical properties which were further verified in colon 
cancer cell lines with differential expression of EGFR and in vivo pharmacokinetic and 
biodistribution studies.  Introduction of the optically active “mitocans” to Bioluminscent 
Resonance Transfer Energy (BRET) studies in cells expressing interactive pairs of 
fluorescently-tagged targets downstream the EGFR pathway, reveals promising potential 
targets of these natural agents. Target verification is achieved with fluorescent molecular 
endoscopy in orthotopic colon cancer models in mice.  These findings are expected to lead 
the way to the identification of specific therapeutic targets for minimally toxic natural agents 
and further decipher their mechanisms of action, thus enabling their development and 
approval as cancer therapeutics.   
 
 Prof. Dusan Popadic 
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Organisation University of Belgrade, Faculty of Medicine 
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Abstract COST Action: European Network for Translational Immunology Research and 
Education (ENTIRE): From immunomonitoring to personalized immunotherapy 
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Abstract Fluorescence based low-cost microbiosensors using simultaneously 
microfabrication process and enzyme immobilisation 
A novel one-step microfabrication process of SU-8 films is proposed for developing 
inexpensive, small size and light-weight optical glucose micro-biosensors. Experimental work 
was performed in order to investigate whether the widely used in MEMS applications SU-8 
photoresists polymers, can be utilised as immobilisation matrices for the simultaneous 
encapsulation of an oxygen-sensitive fluorescent indicator and glucose oxidase. The enzyme 
immobilisation, the encapsulation of the indicator and the patterning of the SU-8 take place 
simultaneously, thus offering a significant simplification of the microfabrication process. 
Despite the process involved contact with organic solvents, UV-light exposure and heating for 
pre- and post-bake, and the embedding of the enzyme in a hard and rigid epoxy resin matrix, 
it was observed that the enzyme demonstrated activity after encapsulation in SU-8. Testing of 
the immobilised enzyme´s activity inside the SU-8 matrix, was carried out with the 
measurement of oxygen consumption using an oxygen-sensitive indicator during the 
enzymatic oxidation of glucose. Negligible variation in fluorescence intensity upon the 
addition of glucose was observed in films without enzyme, whereas films with encapsulated 
enzyme and oxygen-sensitive fluorescent indicator showed a very clear increase in 
fluorescence intensity upon addition of glucose. A high transparency and negligible 
fluorescence of the SU-8 films were observed. The presented work opens up new 
possibilities for combining BioMEMS, advanced optoelectronic components with smart 
biosensor technology for personalised medicine diagnostic applications. 
 
 Dr Giovanni Roviello 
Position Contract Researcher 
Organisation Consiglio Nazionale delle Ricerche - CNR 
Department Institute of Biostructures and Bioimages - IBB 
Town Napoli 
Country Italy 
E-mail giovanni.roviello@cnr.it 
Abstract Nucleobase-containg molecules and biomedicine 
Nucleobase-containing amino acids, (nucleoamino acids) and peptides (nucleopeptides) are 
molecules of increasing interest in biomedicine due to their useful binding properties towards 
natural targets such as nucleic acids and proteins [1], as well as their high resistance to 
enzymatic degradation [2]. More particularly, the binding ability of such molecules towards 
DNA, RNA and proteins is a fundamental feature useful to modulate those biochemical 
processes in which nucleic acids and proteins play a key role. The stability in sero is another 
appreciable characteristic of nucleoamino acid-based molecular probes, also in consideration 
of the scarce enzymatic resistance of natural oligonucleotides. Some nucleoamino acids and 
nucleopeptides are natural like the antimicrobial peptidyl nucleosides or the wiillardiine-
containing peptides recovered from vegetal sources (Fagus sylvatica). However, many 
examples are also known of artificial nucleobase-containing amino acids and peptides which 
were obtained by chemical synthesis both in solution and in solid phase as previously 
reported in literature [2]. In this work, we report some examples of nucleoamino acid-based 
compounds which were recently studied for their possible utilization in biotechnological and 
medical strategies. More particularly, a description not only of their structural characteristics 
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but also of the synthetic routes to these hybrid molecules, as well as some properties of 
molecular interaction which could be beneficial in the development of innovative drugs for 
anticancer and antiviral therapies will be presented.  
References: 
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Abstract Drug metabolism and individualized medicine 
“Personalized medicine” is a new concept in healthcare, one aspect of which defines the 
specificity and dosage of drugs according to effectiveness and safety for each patient. 
Dosage strongly depends on the rate of metabolism which is primarily regulated by the 
activity of cytochrome P450. In addition to the need for a genetic characterization of the 
patients, there is also the necessity to determine the drug clearance properties of the 
polymorphic P450 enzyme. 
It is well-recognized that patients administered a particular drug will exhibit significant inter-
individual variability in their response to treatment. Unfortunately some patients will fail to 
respond to the therapy entirely, while some others will suffer dose-related side effects, 
resulting in significant costs and fatalities. For these reasons, polymorphism in genes 
encoding the drug metabolizing cytochromes P450 is a very important factor that can no 
longer be neglected in the development of new drugs. 
Progress in the human genome analysis has recently made it possible to identify a patient’s 
cytochromes P450 make up by genotype analysis using the AmpliChip CYP450 Test 
available from Roche Diagnostics. 
However, genotyping needs a parallel enzyme-based platform capable of rapidly measuring a 
drug’s pharmacokinetics and clearance by the polymorphic P450 enzymes typical for a given 
genotype, and to this date, such platform is not available; this will be the subject of the current 
presentation. 
 
 Dr Ashutosh Tiwari 
Position Assistant Professor 
Organisation Linköpings Universitet 
Department IFM-Biosensors and Bioelectronics Centre 
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Country Sweden 
E-mail ashutosh.tiwari@liu.se 
Abstract Guar gum-graft-poly(ε-caprolactone) nanocarrier for anti-cancer drug delivery 
Amphiphilic guar gum grafted with poly(ε-caprolactone) (GG-g-PCL) was fabricated as a drug 
delivery carrier using microwave irradiation technique. The structure of the GG-g-PCL 
copolymer was characterized by 1H NMR spectroscopy. By microwave irradiation, the GG-g-
PCL with high grafting percentage (>200%) was achieved in a short reaction time. The GG-g-
PCL copolymer is capable of self-assembling into nanosized spherical micelles in aqueous 
solution with the diameter of around 75-135 nm and 60-100 nm determined by DLS and TEM, 
respectively. The critical micelle concentration (CMC) of GG-g-PCL was found to be ~0.56 
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mg/L in a phosphate buffer solution. The drug release profile showed that the GG-g-PCL 
micelles provided an initial burst release followed by a sustained release of the entrapped 
hydrophobic model drug, ketoprofen, over a period of 10 to 68 h. The GG-g-PCL copolymer 
hydrolytically degraded into lower molecular weight fragments within a seven-week period 
under physiological conditions. These results suggest that the GG-g-PCL micelles could be 
used as a nanocarrier for in vitro controlled drug delivery. 
 
 Dr Natal van Riel 
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Abstract Towards a Personalised Virtual Diabetic Patient Simulator 
The development of a diabetes simulator, an educational software tool which can help 
diabetic patients to better manage their disease, is described. Education of patients with 
diabetes mellitus is a fundamental part of diabetes care. One of the goals of diabetes 
education is to support the patients to understand the nature of their illness and its treatment. 
Diabetes patients should be aware of the impact of nutrition, physical activity and insulin 
injections on blood glucose excursions. They should be able to identify emerging health 
problems like severe hyperglycemia or hypoglycemia in early stages. This will enable them to 
adapt to and prevent these conditions. 
Personalised ICT services provide several possibilities to improve patient education and 
therefore diabetic care. In particular the development of an educational diabetes simulator is 
considered. Only one diabetes simulator, called AIDA, is currently available. AIDA is 
designed only for type-1 diabetes patients (5-10% of the whole diabetic population), and does 
not use patient-specific data.  
We are developing the Virtual Diabetic Patient Simulator (VDPS) for both type-1 and type-2 
diabetes. The VDPS represents the key characteristics and behaviour of the main processes 
of glucose metabolism involved in diabetes for a period of one day (24 hours). Based on 
patient-specific information (parameters) and daily life situations the VDPS can be used to 
train the patient in a virtual environment with realistic scenarios.  
The core of the simulator is a computational model which calculates temporal glucose and 
insulin plasma profiles in response to known inputs (food, insulin, etc.). As a first step we 
have coupled and modified existing literature models. The current model can predict plasma 
glucose concentrations with acceptable accuracy for education purposes. In conclusion, the 
model provides a solid background for further developments of the diabetes simulator. 
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Abstract Machine Learning Methods for the Prediction of Human Prostate Cancer 
Diagnosis and Prognosis, based on Real-Time RT-PCR data from formaline-
fixed and paraffin embedded tissue 
Authors: Anna Vendramin1, Paolo Sonego2, Guido Cappuccilli2, Simeone Dal Monego2, Marco De Simone2, 
Annalisa Hauser2, Alessandra Petrucco1 and Andrea Saccani1 1EuroClone S.p.A., Research Laboratory c/o AREA 
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Science Park, s.s. 14 km 163.5 Basovizza, 34149 Trieste, Italy 2Cluster in Biomedicine (CBM) s.c.r.l., AREA Science 
Park, s.s. 14 km 163.5 Basovizza, 34149 Trieste, Italy 
Background: Prostate cancer (PC) is the most common cancer diagnosed in men today. At 
present, screening methods lack for early stage diagnosis, and new tools are needed in order 
to improve the sensitivity of conventional diagnosis. 
The aim of the study was to evaluate the diagnostic and prognostic power of an 8-gene 
signature in PC detection, using real-time RT-PCR data to train computational predictors 
based on supervised learning methods. 
Methods & Findings: Molecular profiling was obtained from a previously characterized set of 
90 formaline-fixed and paraffin embedded (FFPE) tissue samples from prostate gland: 64 
were diagnosed with PC and 26 were used as negative controls. 
We focused our attention on 8 genes previously shown to be correlated with prostate tumor 
progression: growth arrest-specific gene 1, histone H3, spermidine/spermine N(1)-acetyl 
transferase, ornithine decarboxylase, ornithine decarboxylase antizyme, denosylmethionine 
decarboxylase, clusterine, glyceraldehyde 3-phosphate dehydrogenase. 
The real-time RT-PCR data were used to create different dataset from different PC tissue 
specimens and from negative controls. In order to obtain an effective predictor capable of 
discriminate between the two conditions, we evaluated the performance of various state of art 
supervised learning methods (Support Vector Machines, k-Nearest Neighbours, Random 
Forest) selecting the optimal parameters and features (subset of the 8 signature genes) in 
order to achieve the higher prediction. 
We found that the SVM-based predictor showed a very good performance discriminating PC 
specimens from negative controls through a subset of 4-genes expression profile. The 
concordance of our 4-gene signature with the histological classification is 90.25%, with 93.4% 
sensitivity for prostate cancers and 80.95% specificity for negative controls. We then used the 
same approach to give a prognostic prediction of PC cases, classifying patient’s molecular 
data in three different classes based on Gleason score’s intervals, which represent the best 
predictor of final outcome routinely used in clinical practice. 
The best prognostic prediction was achieved using a Support Vector Machines classifier with 
a 2-genes expression profile which brings to a 73.02% of concordance with the Gleason 
histological classification. All the computational predictors developed in this work were also 
integrated in a prediction server (PCPred) that allows the management of database of cases 
and the submission of prediction jobs via internet browser. 
Discussion: The use of a subset of the original panel of 8 genes (feature selection) in order to 
optimize the performance of different classifiers allows the selection of an optimal predictor 
(Support Vector Machines here) capable to distinguish with high accuracy between tumours 
and benign samples. The method may be of help in supporting conventional PC diagnosis 
and provides an useful prognostic evaluation of the clinical outcome of patients with prostate 
cancer. 
Keywords: prostate cancer, diagnosis, prognosis, prediction, biomarkers, bioinformatics, 
machine learning, prediction server 
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Abstract Non-inasive Investigation of Tissue Morphochemistry by All-Optical Methods 
"In this contribution we will discuss the combination of different optical microspectroscopic 
tools to non-invasively investigate the morphochemistry of human tissue. In particular, we 
combine the chemical sensitivity of nonlinear Raman-scattering (using coherent anti-Stokes 
Raman scattering, CARS) with second-harmonic generation (SHG) imaging to visualize the 
distribution of collagene and two-photon excited-fluorescence (TPF) imaging highlighting the 
distributions of fluorescent cofactors in the tissue. As the nonlinear optical tools are non-
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invasive they can principally be used in personalized medicine for an in-vivo accessment of 
the physiological state of tissue. Furthermore, we shall discuss recent approaches towards 
automated image segmentation, pattern recognition and data classification, which present 
indispensible bioinformatic tools to bring this all-optical approach into the clinics." 
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Abstract Even stressed cells are individuals: Second messengers of free radicals in 
pathophysiology of stress associated diseases  
"Pathophysiological processes associated with misbalance of oxidative stress and tissue 
homeostasis are associated also with lipid peroxidation. The end products of oxidative stress 
are therefore reactive aldehydes such as 4-hydroxy-2-nonenal (HNE), which act as a “second 
messengers of free radicals”.  
Findings of growth regulating activities of HNE that overlapped with the development of the 
monoclonal and polyclonal antibodies specific for the HNE-protein adducts led to the 
introduction of qualitative determinations of the HNE presence in various (patho)physiological 
processes and to the change of consideration of the aldehyde’s bioactivities from cytotoxicity 
into cell growth regulation and signalling.1,2  
However, the appearance of HNE in various organs indicates that it pathophysiology might be 
related to the cellular individuality of the stress reaction and adaptation that are not 
understood yet. 
Neven Zarkovic (2003) 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. Mol Asp Med, 
24:281-291 
2 Anne Negre-Salvayre, Nathalie Auge, Victoria Ayala, Huveyda Basaga, Jordi Boada, Rainer Brenke, Sarah 
Chapple, Guy Cohen, Janos Feher, Tilman Grune, Gabriella Lengyel, Giovanni E. Mann, Reinald Pamplona, 
Giuseppe Poli, Manuel Portero-Otin, Yael Riahi, Robert Salvayre, Shlomo Sasson, Jose Serrano, Ofer Shamni, 
Werner Siems, Richard C. M. Siow, Ingrid Wiswedel, Kamelija Zarkovic, Neven Zarkovic  (2010) Pathological 
aspects of lipid peroxidation. Free Radical Research, 44:1125-1171 
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Abstract Finding combinatorial drugs from traditional Chinese medicines 
To address the “more investments, less drugs” challenge in drug development, more and 
more attention is paid to multicomponent therapeutics. This drug discovery strategy will take 
many advantages over the prevalent single-component paradigm. However, to implement the 
new strategy, we still have to cope with some challenges, such as the explosive increase of 
drug combination quantities, the unpredictable pharmacokinetic properties of multiple 
components and the potential risks of drug-drug interactions. In spite of the rapid technical 
progresses in high-throughput screening, high-content screening and systems biology and 
various “omics”, we still need a long time to perfect the related techniques. Since traditional 
medicines, in particular traditional Chinese medicine (TCM), have accumulated rich 
experiences in combinatorial use of natural medicines (for instance, more than 100,000 
58 
 
formulae have been documented in TCM). We speculate that we can start with traditional 
medicines to find modern drug combinations. This tactic is preliminarily supported by the 
finding that a certain part of TCM components have counterparts of modern Western drugs or 
candidates and the synergistic effects of some TCM formulae can be understood in terms of 
the Western-medicine-justified activities [1]. In addition, starting with traditional medicines will 
take the advantages of controlling the pharmacokinetics and drug-drug interactions of 
multiple components, because most combinatorial modes of TCM combinations have been 
used clinically for hundreds years and by thousands of patients (if not millions). To further 
evaluate the potential of this tactic, we will focus on anti-dementia TCM formulae to examine 
whether some clues can be derived from these prescriptions to help find anti-dementia 
combinatorial drugs [2].  
References 
De-Xin Kong, Xue-Juan Li, Guang-Yan Tang, Hong-Yu Zhang. ChemMedChem, 2008, 3: 233-236.  
De-Xin Kong, Xue-Juan Li, Hong-Yu Zhang*. Drug Discov. Today, 2009, 14: 115-119.  
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Abstract In-body positioning using enhanced radio signal strenght 
Specifics of in-body positioning of a wireless capsule using received radio signal strength 
(RSS) on the body's surface will be presented. Limits on three axial accuracy for capsule 
positioning and orientation will be discussed. A new method for enhanced RSS positioning 
using a sensor network will be presented. Energy and space requirements will be compared 
with physical capsule limitations as well as those of other positioning and orientation 
detection methods. Simulation results using SEMCAD X Medical full human body phantoms 
to acquire radio signal data and software package for wireless capsule positioning developed 
in MATLAB will be presented. Finally, conclusion on achievable accuracy and feasibility of 
enhanced RSS in in-body positioning will be given. 
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